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ABSTRACT 
The study of adherence to antiretroviral therapy among HIV positive Injection Drug 
Users (IDUs) has been largely neglected. Many clinicians believe that this group is too 
unreliable to take these medications, particularly in the early stage of their recovery 
from drug abuse when they are vulnerable to relapse. This is the first study of its kind 
to compare medication adherence rates between HIV positive injection drug users and 
non-users. 
The medication adherence among IDUs and non-IDUs was compared in an HIV 
infected population (n=143) who were currently on antiretroviral therapy. The factors 
affecting medication adherence were also examined in the same population. Data on 
demographics, clinical characteristics, mood status, physical functioning and social 
support was obtained. Medication adherence was measured using the "Temptation to 
skip antiretroviral medication scale" and "Percent of doses missed in the past week, 
month and three months". 
Multiple T-tests conducted on the data revealed that IDUs and non-IDUs had no 
distinction in medication adherence behavior (p<0.05). Therefore, further group 
difference analyses such as multiple T-tests and Chi-Square tests were done on all 
other independent variables to look for possible confounders. 
11 
These bivariate analyses showed that IDUs were older, sicker, less educated and had a 
longer duration of HIV positive status than non-IDUs. IDUs were also found to have 
worse mental health, more severity of bodily pain and more interference of pain with 
normal work than non-IDUs. 
Multiple ANCOV As conducted to control for these possibly confounding factors, 
however showed no significant differences in medication adherence between IDUs 
and non-IDUs. These results suggested that age, severity of disease, educational level, 
duration of seropositive status, general mental health, severity of bodily pain and pain 
interfering with normal work did not affect medication adherence in HIV positive 
IDUs and non-IDUs. 
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INTRODUCTION 
A. Importance of Adherence to Antiretroviral Therapy 
Adherence, often used interchangeably with compliance, is the act, action, or quality 
of being consistent with administration of prescribed medications [Altice FL et al, Ann 
Intern Med, 1998]. Non-adherence may mean not taking medication at all, taking 
reduced amounts, not taking doses at prescribed frequencies or intervals, or not 
matching medication to food requirements [Altice FL et al, Ann Intern Med, 1998]. 
Critical data on exactly how much adherence to antiretroviral therapy is enough, and 
how little is too little, are lacking [Sherer R, JAMA, 1998]. However, the association 
between poor adherence and virologic failure with resistance has been clearly 
established [Sherer R, JAMA, 1998; Montaner Jet al, 1996]. 
Adherence to HIV therapies presents special issues that result from the biology of 
HIV, the magnitude of therapeutic effort, and the changing demography of HIV 
infection [Altice FL et al, Ann Intern Med, 1998]. The replication of the virus is rapid 
and highly error-prone, resulting in great species diversity and new drug-resistant 
mutants unless replication is completely suppressed. Cross-resistance among drugs 
within a therapeutic class limits future treatment options. Thus, the development and 
transmission of antiretroviral-resistant species carries potentially disastrous public 
health consequences. In theory, if patients are 100% adherent to potent combination 
therapy, viral replication will most likely be halted and development of drug-resistant 
mutants is unlikely. However, in patients who intermittently or irregularly take drugs, 
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the likelihood of selection of mutants that are resistant to drugs increases, a 
consequence of both continuing viral replication and selective automicrobial pressure 
[Friedland G, JAMA, 1998]. Thus, improvement in adherence is thought to be key to 
preventing the emergence of drug-resistant viruses that compromise therapeutic 
benefit and may be transmitted to others. The cost of interventions to enhance 
adherence is minimal compared with the cost of the therapies themselves and should 
be weighed against the costs to individual patients and to society resulting from 
compromised therapeutic benefit [Altice FL et al, Ann Intern Med, 1998]. 
The study of adherence to antiretroviral therapy among HIV positive injection drug 
users (IDUs) has been largely neglected. Many clinicians believe that this group is too 
unreliable to take these medications, particularly in the early stage of their recovery 
from drug abuse when they are vulnerable to relapse [Bangsberg D et al, JAMA, 1997; 
Malow RM et al, Psyc Serv, 1998]. However, no studies have clearly demonstrated 
this association. Several complex factors influence adherence to antiretroviral 
medications in HIV positive IDUs. In order to develop interventions that would 
maximize adherence to antiretroviral therapy in IDUs, it is essential to consider the 
factors affecting adherence in this group of people. 
This study will determine if IDUs are less adherent than non-IDUs towards HIV 
therapies and will identify factors associated with adherence. 
2 
B. Determinants of Adherence 
Over the years, researchers have determined several factors associated with 
medication adherence in general. These factors can be broadly categorized as patient 
characteristics, clinical characteristics and psychological and emotional characteristics. 
Patient Characteristics: Sociodemographic variables such as age, sex, education, 
income, race and ethnicity have shown some correlation with adherence but not 
consistently and not at significant levels [Freeman et al, 1996; Cummings et al 1982; 
Davis, 1968; Haynes et al, 1979]. Majority of the studies on medication adherence 
show no association between noncompliance and lower socioeconomic status, poor 
education and older age [Haynes et al, 1979]. Social support is probably the most 
important factor among patient characteristics associated with adherence [Friedland G, 
1998]. 
Clinical Characteristics: Haynes (1979) has commented after critically reviewing the 
literature that there are few obvious associations between disease features and 
compliance. The one association between illness and nonadherence that is consistently 
reported is that when patients get better from an illness they are less likely to adhere to 
the treatment [Heinzelman, 1962; Johnson, 1973; Prien & Caffey, 1977]. 
Psychological and Emotional Characteristics: These are said to play a greater role in 
determining medication adherence than demographic characteristics. One of the 
important characteristics in this group is Mood Status. 
Mood Status: A level of anxiety either too low or too great may well be related to 
noncompliance [Evans L et al, Drugs, 1983]. Studies in HIV suggest that psychosocial 
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stress associated with the illness adversely affects the quality of life in HIV patients 
[Fawzy et al, 1989; Holland et al , 1985; Solomon et al, 1989]. Many of the cognitive, 
psychological, social and environmental factors that determine the individual' s 
psychosocial well-being and quality of life also have an impact on compliance. 
The SF-36 (Short-Form-36) derived from the work of the Rand Corporation of Santa 
Monica during 1970 is a generic indicator of health status. It was designed to be 
applicable to a wide range of types and severities of condition. These were useful for 
monitoring patients with multiple conditions, for comparing the health status of 
patients with different conditions, and for comparing patients to the general 
population. Perceived well-being is subjective and cannot be completely inferred from 
behavior; hence the SF-36 included questions on feeling states [Mc Dowell I et al, 
Measuring Health, 2"d edition, p 446] . 
To summarize, many factors have been associated with medication adherence, 
including patient characteristics, clinician-patient relationship, type of disease, 
treatment regimen, and clinical setting [Altice FL, et al, 1998; Ickovics JR, et al, 
1997]. Gender, age, race, socioeconomic status, educational level, and a history of past 
substance use are not predictors of poor adherence to treatment, although active drug 
or alcohol use are [Sherer R, 1998; Klaus BD, 1997]. Adherence improves with a 
relationship with a trusted, accessible physician; this is particularly critical for the care 
of ID Us [Sherer R, 1998; O'Connor PG, 1994]. Asymtomatic and chronic diseases are 
less likely to have high rates of adherence, and complex treatment regimens decrease 
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adherence [Altice FL, et al, 1998]. The organization of clinical services can affect 
adherence, including availability of expertise, linkages with drug treatment and mental 
health services, flexibility in the hours of operation, and the presence of 
nonjudgmental and supportive staff [Altice FL, et al, 1998; Morse EV, 1991]. 
Compared with therapies for other chronic diseases, which are often forgiving of 
lapses in adherence, HIV therapy is unforgiving [Altice FL, et al, 1998]. This is 
because, under the selective pressure conferred by imperfect adherence to 
antiretroviral therapy, drug-resistant mutants rapidly emerge. 
C. Assessment of Adherence 
There is no ideal method to assess drug compliance. Four methods, commonly used to 
measure compliance, are as follows: 
Self-Reported Questionnaire: This method is commonly used as it a relatively simple 
and an inexpensive method. Sometimes it may be the only method available. The 
interview method is particularly useful in evaluating problems the patient may have 
and the factors that enhance adherence. Highly accurate data should not be expected, 
however, particularly if adherence data is being assessed over a fairly long time 
period. Though this method may not be accurate there may be reason to believe it is 
useful because patients reporting noncompliance are usually at least as noncompliant 
as indicated by interview [Norell SE, Soc Sci Med, 1981 ]. When compared with other 
measures the interview tends to overestimate adherence [Dunbar J, 1984]. A review 
conducted by Adams and Soumerai states that in 87% of 37 comparisons, self-reported 
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adherence rates exceeded the objective rates, resulting in a median overestimation of 
adherence of 27% [Adams AS et al, 1999]. Using face-to-face interviews for patients' 
reports about medication-taking behavior have been found to get higher quality 
information than do survey instruments [Ickovics JR et al, 1997]. 
Pill Count: Corrigan and Strauss described the method of counting tablets to 
determine patient medication behavior in 1936 in a study of iron treatment for anemia 
[Davis MS et al, 1966]. Since then, several techniques based on the same principle 
have been described. This method involves a comparison of the medicine left in the 
patient's bottle and the quantity that should have been left if the medication had been 
taken. Though this method is being used extensively, it is not believed to be very 
accurate. Patients may empty the pillbox, or take all the remaining pills before their 
clinic visit [Gray L et al, 1998]. 
Drug Assay: The accuracy of this method depends in part on the half-life of the drug 
[Gray L et al, 1998]. This means that it depends on how soon the drug reaches the 
systemic circulation so as to be detected in a drug assay. Longer-acting indicators have 
been used, but testing will show only past ingestion and not frequency or dosing 
interval. These studies are very inconvenient and can be expensive. Patient-to-patient 
variability is another disadvantage of this method. Some patients may object to having 
their blood specimen taken, regarding this as unnecessary and intrusive. Again the 
value of assessing compliance in this way depends greatly on the reliability of the 
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method by which the drug is identified or quantified in body fluids [Eldred et al, 
1998]. 
Medication Event Monitoring System (MEMS): This method provides a computer chip 
in the cap of the medicinal bottle. Information is recorded each time the bottle is 
opened. Data from the MEMS allows calculation of 1) the compliance rate, 2) 
prescribed frequency, and 3) prescribed interval. This method also does not directly 
measure whether the medication was taken by the patient; hence the accuracy of this 
method is suspect [Gray L et al, 1998]. A study of adherence in patients on 
antiretroviral therapy revealed that while the overall compliance rate was 82% to 86%, 
more detailed measures of the fraction of doses taken at the prescribed daily interval 
(55-77%) and fraction of doses taken at the prescribed dosing interval (27%) were 
lower [Friedland G, JAMA 1997]. 
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3. Veterans' Affairs Medical Center in Providence, RI, which currently provides care 
to approximately 60 HIV seropositive men. 
For the purposes of this study, we were interested only in persons taking antiretroviral 
medications. Therefore two subjects who were on a protease inhibitor alone were 
dropped from the study population. This reduced the population size to 143 subjects. 
B. Data Collection 
Patients meeting the above criteria who visited one of the three sites were asked to fill 
out a standardized questionnaire. The patients were told that the questionnaire was 
about how they think and feel about the HIV related medications that they were 
taking, and about different strategies that people use to take their medications. They 
were given the choice of filling out the questionnaire at home and mailing it in or 
returning it to the clinic, or filling it out at the clinic. They were also told that they 
would each receive a gift certificate of $20 after they had filled out the questionnaire. 
The data was collected during the year 1996-97. 
The survey questionnaire administered to patients included data on demographics, 
living arrangements, education, employment, income, insurance coverage, social 
support, side effects and psychological measurements scales. It was a self-reported 
questionnaire. All the questionnaires were checked for completeness. 
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C. Measures and Variables assessed 
Patients were asked to complete questionnaire items concerning the following: 
Demographics: age, gender, race, educational level, health insurance coverage, 
family income, number of people in household. 
Clinical Characteristics: The following questions assessed clinical variables: 
1. T-cell count when last tested 
2. Cause of contracting HIV infection 
3. Duration since HIV positive. 
Mood Status: The scale was taken from the SHORT-FORM-36 HEALTH SURVEY 
developed by Rand Corporation and John E. Ware (1990). It was designed as a generic 
indicator of health status for use in population surveys and evaluative studies of health 
policy. 
This scale measured the following dimensions: 
General Mental Health, covering psychological distress and well-being (five item: 
questions b, c, d, f and h) 
Vitality, Energv or Fatigue (four item: questions a, e, g and i) 
The questions were measured on a six point likert scale from none of the time (score 
of 1) to all of the time (score of 6). 
The questions were as follows: 
a. Did you feel full of pep? 
b. Have you been a very nervous person? 
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c. Have you felt so down in the dumps that nothing could cheer you up? 
d. Have you felt calm and peaceful? 
e. Did you have a lot of energy? 
f. Have you felt downhearted and blue? 
g. Did you feel worn out? 
h. Have you been a happy person? 
i. Did you feel tired? 
Scoring: Answers on questions a, d, e and h were recoded (i.e. score of 1 was changed 
to score of 6, score of 2 was changed to score of 5 and so on) such that low values 
represented more favorable states. Further, scores on questions b, c, d f and h were 
summed up to obtain the raw score for each individual's General Mental Health. 
Similarly, scores on questions a, e, g and i were added to get the raw score of each 
individual on Vitality, Energy or Fatigue. Finally, transformed scores on each of the 
two measures were obtained by using the following formula: 
Transformed scale= (actual score - lowest possible score)* 100 
Possible raw score range 
Physical Functioning: The following questions assessed physical functioning: 
1. Severity of bodily pain 
2. Number of days in bed in the past two weeks 
3. Number of hospitalizations in the past year 
4. Interference of pain with normal work in the past four weeks. 
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Social support: Support in the form of financial support and emotion support was 
assessed using the following two questions: 
1. How many of your family or friends can you count on for emotional support? 
2. How many of your family or friends can you count on for financial help? 
D. Assessment of Medication Adherence: 
Two measures were used to assess medication adherence. They are as follows: 
1. Temptation to skip medication: This scale was developed to measure the self-
reported likelihood of non-compliance (Willey, C et al, manuscript in progress). The 
items on the temptation scale were based upon predictors of compliance from the 
literature and included situations that might affect you taking your antiretroviral 
medications as directed. Responses for each situation rated how tempted you would be 
to skip your antiretroviral medication. The responses were measured on a five-point 
likert (continuous) scale with 1 =not tempted to 5 =extremely tempted. 
Examples of items on this scale are as follows: 
• When you feel good and you don't need it 
• When you are anxious about side effects 
• When you want to save on cost of medication 
• When your doctor doesn't seem interested in whether you take your medication 
• When you start feeling better 
Three subscales were developed for this scale as follows: 
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a. Temptation to skip medication due to side effects 
• When you are anxious about side effects 
• When you experience minor side effects 
• When you feel you should give your body a rest 
• When you worry that the chemicals in the medication might harm or hurt your body 
b. Temptation to skip medication due to lack of social support 
• When your family and friends don't seem concerned enough about your condition 
• When your doctor doesn't seem concerned enough about your condition 
• When your insurance doesn't cover the cost of your medication 
• When you lose confidence in your doctor 
c. Temptation to skip medication when feeling good 
• When you good and think you don't need it 
• When your medical condition doesn't seem that bad 
• When it seems too complex to keep track of all your medications 
• When you aren't sure if the medicine is really helping you 
Scores on each subscale were obtained by adding items under each subscale. 
For example, Score on temptation to skip medication due to side effects = (QIII24 + 
QIII28 + QIII51 + QIII52). 
d. Total scale 
Scores on the total scale were obtained by summing all scores under all the subscales. 
2. Percent of doses missed: This measure was divided into three subgroups: 
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a. Percent of doses missed during the past week 
b. Percent of doses missed during the past month 
c. Percent of doses missed during the past three months 
This variable was continuous and calculated using the self-reported answer to the 
question on 'number of doses missed'. The question 'how often do you take this 
medication' was used to determine to total doses prescribed for each medication. 
For example: 
For patients answering 'two times a week' to 'how often do you take your 
medication'; 
% of doses missed during past 1 week = ( 100 * # of doses missed during past 1 week) 
2 
% of doses missed during past month = ( 100 * # of doses missed during past month) 
8 
% of doses missed during past 3 months = (100 * # of doses missed during past 3 
mths.) 
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Similarly, the percent of doses missed were calculated for each response to the 
question 'how often do you take your medication'. This however led to the loss of data 
on five subjects who answered 'other'. Percent of doses missed were separately 
calculated for each medication for patients on multiple medications and summed i.e. 
% of doses of Medication 1 missed + % of doses of Medication 2 missed + % of doses 
of Medication 3 missed and so on, to get one value for the total percent of doses 
missed. Higher numbers of percent of doses missed indicated worse compliance. 
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E. Selection of Variables for Data Analysis: 
The following variables were determined to be of interest and were further categorized 
for use in additional analyses: 
Dependent Variables: 
1. Percent of doses missed: 
a. In the past week 
b. In the past one month 
c. In the past three months 
2.Temptation to skip medication: continuous 
a. Total scale 
b. Due to side effects 
c. Due to lack of support 
d. When feeling good 
Independent Variables: (Categorical variables were dummy coded). 
The IV of primary interest was IDU/non-IDU (1/0). The question 'how do you think 
you got your HIV infection' was used to code this variable. Persons who checked 
'injection drug use' were assigned the code IOU = 1 and all others were assigned the 
code IOU= 0. 
1. Demographic Variables 
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Age: continuous 
Gender: 
0 =Male 
1 =Female 
Current health status: 
0 =Fair to Poor 
1 = Excellent to Good 
Race: 
0 =Non-whites 
1 =Whites 
Years of education: continuous 
Insurance coverage: 
0 = No insurance 
1 = Some insurance 
Annual income: 
0 = <$15,000 
1 = $15,000+ 
Number of persons in household: continuous 
2. Clinical Variables: 
Duration since HIV positive: 
0 = <5 years 
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1=5+ years 
T-cell count when last tested: 
0 =>200 
= </= 200 
3. Mood Status Scale: 
General Mental Health: continuous (GMH) 
Vitality, Energy or Fatigue: continuous (VEF) 
4. Physical Functioning Variables: 
Bodily pain in past 4 weeks: 
0 =None 
1 = Very Mild to Very Severe 
Pain interfering with normal work in past 4 weeks: 
0 =Not At All 
1 = A Little Bit to Extremely 
Number of days in bed in past 2 weeks: continuous 
Number of hospitalizations in past year: continuous 
5. Support Variables: 
Persons giving emotional support: continuous 
Persons giving financial support: continuous 
17 
F. Data Analysis 
The categories mentioned above constitute the independent and the dependent 
variables. The data was analyzed using the Statistical Analysis System (SAS) Version 
8 on an IBM compatible computer at the University of Rhode Island. Bivariate and 
multivariate statistical techniques were used to examine the association between the 
dependent (DV) and the independent (IV) variables. Pre-analysis screening procedures 
were used to assess the normality, linearity and homoscedasticity of the data. Plots of 
DV s versus IVs were plotted to check for outliers. PROC UNIV ARIA TE procedures 
were carried out to check for skewness and kurtosis. Collinearity diagnostic 
procedures were carried out to check for possible cases of multicollinearity. The 
variable ' insurance' consisted of ten categories of insurance type (e.g. Medicaid, 
Medicare, Blue Cross, etc). Since we were interested only in whether our patients had 
some insurance coverage as opposed to none and not in what type of insurance 
coverage, two new categories were created under this variable (no insurance vs. some 
insurance). 
Multiple T tests were carried out to test for group differences between IDUs and non-
IDUs on all the dependent variables. This was done the see whether IDUs differed 
significantly from non-IDUs in their medication adherence behavior. 
Multiple T tests were also performed on all continuous IVs to check for group 
differences between the two groups - IDUs and non-IDUs. Chi-Square Tests were 
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used to evaluate group differences between IDUs and non-IDUs for all dichotomized 
IVs. Follow up ANCOVAs were conducted on those IVs (continuous and 
dichotomous) that showed significant ANOVAs 
The Bonferroni correction would be applied where necessary. This is a method 
developed to deal with problems arising from multiple tests. In any significance test 
the probability of making a Type I error is equal to the significance level. Thus, at a 
significance level of 0.05 there is a 1 in 20 chance of making a Type I error. 
The correction consists of adjusting the significance level by correcting for the number 
of tests. The adjusted significance level is alpha/k, where alpha is the desired 
significance level and k is the number of hypotheses being tested. 
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RESULTS 
A total of 145 patients were enrolled in the study. One hundred and forty three (143) 
patients were on antiretroviral therapy, which comprised the study population. As seen 
from Table 1, the study sample was predominantly male (70.63%). The median age 
was 39 years and it ranged between 24-57 years. Only 4% (6/143) patients reported 
poor health status. Sixty three percent (90/142) were white, 16% were African 
American, 11 % were Hispanics and only 3% were Native Americans. Thirty four 
percent (48/143) had less than 12 years of education. Fifty-three percent (71/143) lived 
alone or had one other person living with them. More than half the study population 
(63%) had annual income less than $15,000. Majority of the patients (82%) had no 
insurance coverage of any kind. 
Thirty nine percent (56/143) patients reported having used injection drugs [Table 2]. 
Only 13% (19/136) patients had T-cell counts less than fifty. More than half the study 
sample (66%) had been diagnosed as HIV positive for a period of 5 years or more. 
Descriptive statistics for the mood status variables of the study population are given in 
Table 3. The median score on both the General mental health variable and the 
Vitality, energy or fatigue variable was 0.392 and the values ranged from 0 to 1. 
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Only 4% (5/143) patients reported having very severe bodily pain in the past four 
weeks. Thirty three percent (47/143) patients reported that pain had not interfered with 
their normal work in the past four weeks [Table 4]. 
As seen from Table 5, the median value for number of persons giving emotional 
support was 8 and it ranged from 0 to 60. The median value for number of persons 
giving financial support was 3 and it ranged from 0 to 22. 
A. Table 6 summarizes the results of the Multiple T-tests carried out on all the 
continuous IVs to check for group differences between the two groups - IDUs 
and Non-IDUS: 
The variables age (p=0.0127), years of education (p=0.0373) and general mental 
health (p=0.0084) were found to be significantly different between IDUs and non-
IDUs at the 0.05 level of significance. 
B. Table 7 summarizes the results of the Multiple Chi Square tests carried out on 
all the dichotomous IVs to check for group differences between the two groups -
IDUs and Non-IDUS: 
The variables current health status (p=0.0097), race (p=0.0090), annual income 
(p=0.0002), duration since HIV positive (p=0.0327), severity of bodily pain 
(p=0.0240), and pain interfering with normal work (p=0.0119) were found to be 
significantly different between IDUs and non-ID Us at the 0.05 level of significance. 
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C. Table 8 summarizes the results of Multiple T-tests for the variable of primary 
interest (IDU/non-IDU) and all the dependent variables: 
Injection drug users and non-users showed no significant differences in medication 
adherence at the p value of less than 0.05 on the temptation to skip medication due to 
side effects, due to lack of social support, when feeling good, and the total scale. 
Neither did they show significantly different medication adherence behavior (a=0.05) 
when measured using percent of doses missed during past week, during the past month 
and during the past three months. 
D. Table 9 summarizes the results of multiple ANCOV As for the Temptation to 
skip medication due to side effects scale and the variable of primary interest 
(IDU/non-IDU): 
The ANCOVAs were found to be non-significant at the p-value of 0.05. 
E. Table 10 summarizes the results of multiple ANCOV As for the Temptation to 
skip medication due to lack of social support scale and the variable of primary 
interest (IDU/non-IDU): 
The ANCOVAs were found to be non-significant at the p-value of 0.05 . 
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F. Table 11 summarizes the results of multiple ANCOV As for the Temptation to 
skip medication when feeling good scale and the variable of primary interest 
(IDU/non-IDU): 
The ANCOVAs were found to be non-significant at the p-value of 0.05 
G. Table 12 summarizes the results of multiple ANCOV As for the Temptation to 
skip medication Total scale and the variable of primary interest (IDU/non-IDU): 
The ANCOVAs were found to be non-significant at the p-value of 0.05. 
H. Table 13 summarizes the results of multiple ANCOV As for the Percent of 
doses missed during the past week and the variable of primary interest (IDU/non-
IDU): 
The ANCOV As were found to be non-significant at the p-value of 0.05. 
I. Table 14 summarizes the results of multiple ANCOV As for the Percent of doses 
missed during the past month and the variable of primary interest (IDU/non-
IDU): 
The ANCOVAs were found to be non-significant at the p-value of 0.05. 
J. Table 15 summarizes the results of multiple ANCOV As for the Percent of 
doses missed during the past three months and the variable of primary interest 
(IDU/non-IDU): 
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The ANCOV As were found to be non-significant at the p-value of 0.05. 
K. Table 16 summarizes the results of multiple ANCOV As for the Health Model 
using health related variables as covariates versus IDU/Non-IDU: 
The ANCOV As were found to be non-significant at the p-value of 0.05. 
L. Table 17 summarizes the results of multiple ANCOV As for the Full Model 
using all the independent variables as covariates versus IDU/Non-IDU: 
The ANCOVAs were found to be non-significant at the p-value of 0.05. 
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DISCUSSION 
This study examined differences in adherence to antiretroviral therapy among HIV 
positive injection drug users and non-injection drug users. Two measures of 
medication adherence were employed for this purpose. They were 'Temptation to skip 
medication' (due to side effects, due to lack of social support, when feeling good, and 
Total scale) and ' Percent of doses missed' (during the past week, during the past 
month, and during the past three months). 
A. Differences in medication adherence among IDUs and non-IDUs: 
Interestingly, there were found to be no significant differences m medication 
adherence between IDUs and non-IDUs for this study population on any of the 
adherence measures used. This result is in absolute opposition to what has been 
hypothesized by several clinicians in the past, who believe that HIV positive IDUs are 
less adherent to their medication regimens than non-users. This disparity was thought 
to be due to confounding variables in the data, which in all probability could be 
masking the relationship between medication adherence and injection drug use. 
Therefore, differences m IDUs and non-IDUs on all other variables such as 
demographics, clinical characteristics, mood status variables, physical functioning 
variables and support variables were examined. 
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B. Differences in demographic characteristics among IDUs and non-IDUs: 
There were significant differences in age, current health status, race, years of 
education and annual income between IDUs and non-IDUs. Injection drug users were 
found to be older, sicker, less educated, mostly Hispanics and having less annual 
income than non-users. All or any of these factors, individually or in combination, 
could be confounding the relationship between medication adherence and injection 
drug use. 
C. Differences in clinical characteristics among IDUs and non-IDUs: 
Injection drug users were found to have longer duration of HIV positive status than 
non-users. Many studies in the past have reported that duration since diagnosis of a 
disease may have a significant effect on medication adherence rates. 
D. Differences in mood status variables among IDUs and non-IDUs: 
General mental health as measured by the Mood Status Scale (Ware JE, 1990) was 
found to be worse in IDUs than in non-IDUs. Various studies have shown that 
psychological factors have a greater effect on medication adherence than 
demographics or clinical characteristics. 
E. Differences in physical functioning variables among ID Us and non-ID Us: 
Injection drug users reported more severity of bodily pain and more interference of 
pain with normal work than non-users. Pain can have a physical and emotional impact 
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on an individual. It can limit activities of daily living or cause negative psychological 
responses such as depression, agitation and decreased alertness. Thus, we can expect 
an HIV positive individual experiencing pain to be physically incapable of taking 
his/her medication or psychologically depressed due to pain to want to take his/her 
medication. 
F. Differences in support variables among IDUs and non-IDUs: 
No differences were seen in support variables between IDUs and non-IDUs. 
All the variables that showed significant differences between IDUs and non-IDUs 
were thought of as being possible confounders. 
Hence, the relationship between medication adherence and injection drug use was 
again examined after controlling for all the variables that showed significant 
differences between the two groups (ID Us & non-ID Us) of individuals. 
However, no significant differences were found between IDUs and non-IDUs on any 
of the measures of medication adherence, even after controlling for the possibly 
confounding factors. 
G. Limitations: 
The limitations of this study include use of cross-sectional and self-reported data, 
small sample size and skewed data (probably due to selection bias). In addition, there 
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is no gold standard to measure compliance and researchers are still debating over the 
acceptable range of values for compliance rates in the case of HIV positive patients. 
Self reported data: People may be inaccurate in reporting their behavior. There may 
be multiple factors influencing them in terms of their ability and desire to provide a 
valid response. These factors may include clarity of questions, setting, memory, 
literacy and mood status. 
Measurement: Although there seems to be no gold standard or satisfactory way to 
measure medication adherence, the questionnaire has been designed to cover every 
aspect of the patients' moods, disease status, demographics, temptations, etc. which 
can help us in determining the factors affecting medication adherence to the best of 
our ability. 
Selection Bias: The data obtained from the questionnaires were found to be very 
compliant. This could be the result of selection bias due to which only the more 
compliant HIV positive individuals filled out the survey questionnaires. 
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CONCLUSIONS 
The objective of this study was to compare medication adherence rates in injection 
drug users and non-users. This study is the first of its kind to compare medication 
adherence between HIV positive injection drug users and non-injection drug users. 
This study reported no significant differences in medication adherence between 
injection drug users and non-users. While in the past researchers have held the belief 
that there exists a negative relationship between injection drug use and medication 
adherence, no study has been carried until now which actually compares medication 
adherence rates between IDUs and non-IDUs. 
In the past, several studies have reported that HIV positive injection drug users are 
under-prescribed potent antiretroviral therapy in comparison with non-users. This is 
because clinicians have concerns about the ability of this group of individuals to 
comply with the complex medication regimens. Incomplete adherence or 
nonadherence could lead the development of drug resistant strains of the virus and to 
cross resistance among drugs within a therapeutic class limiting future treatment 
options for all HIV positive individuals. It is thus evident why medication adherence is 
such an important issue in HIV positive injection drug users. The results of this study 
indicate that although injection drug users are no less adherent than non-users, they are 
not being given the optimum treatment required due to erroneous beliefs about their 
ability to comply with complex medication regimens. 
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However, the results of this study cannot be generalized to the entire population due to 
limitations such as cross-sectional, self-reported data and small sample size. In 
addition, it could be due to selection bias that this study found no differences in 
medication adherence between IDUs and non-IDUs. 
Hence in conclusion, further studies, preferably longitudinal, with large, randomized 
samples of the general population and in-depth analyses are required in order to 
accurately understand the relationship between injection drug use and medication 
adherence. 
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Table 1: Demographics of Patient Population (N=143) 
Demographic N (0/o) 
Variables 
Age 
--
Mean=39.15 Min=24.00 
S.D.=7.48 Max=57.00 
Sex 
Females 41 (28.67%) 
--
Males 101170.63°/tl 
Current Health Status 
Excellent 10 (6.99%) 
Very Good 33 (23.08%) Mean=2.94 
Good 61 (42.66%) S.D.=0.96 
Fair 33 (23.08%) Min=l.00 
Poor 6_(_4.20%1 Max=5.00 
Race 
White, non-Hispanic 90 (63.38%) 
Native American 4 (2.82%) Mean=2.22 
Hispanic 16 (11.27%) S.D.=1.79 
Asian 0 (0.00%) Min=l.00 
African American 23 (16.20%) Max=6.00 
Other 9 _(_6.34 °/tl_ 
Education 
<12yrs 48 (33.57%) Mean=2.14 
12yrs 47 (31.47%) S.D.=1.03 
13-15yrs 32 (22.38%) Min=l.00 
16+_yrs 18_112.59%1 Max=4.00 
# In Household 
0-1 person 71 (52.99%) Mean=l.47 Min=l.00 
2+ _l)_ersons 63_147.01%1 S.D.=0.50 Max=2.00 
Annual Income 
Less Than $15,000 84 (62.69%) Mean=l.71 
$15,000 to $24,000 25 (18.66%) S.D.=1.12 
$25,000 to $34,000 9 (6.72%) Min=l.00 
$35,000 to $44,000 12 (8.96%) Max=5.00 
$45,000 or more 4_12.99°/tl_ 
Insurance 
Some 26 (18.18%) Mean=l.18 Min=l.00 
No 117 _(_81.82%1 S.D.=0.39 Max=2.00 
Note: S.D. = Standard Deviation, Min = Minimum Value, Max = Maximum Value. 
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Table 2: Clinical Characteristics of Patient Population (N=143) 
Clinical Variables N_{_%_l 
T-Cell Count 
>500 20 (13.79%) Mean=2.90 
201-500 53 (36.55%) S.D.=0.85 
50-200 44 (30.34%) Min=l.00 
<50 19 (13.10%) Max=4.00 
Duration since IDV+ 
<lmonth 1 (0.71%) 
1-6mths 4 (2.86%) Mean=5.39 
>6mths-<lyr 4 (2.86%) S.D.=1.05 
1-2 yrs 14 (10.00%) Min=l.00 
3-4 yrs 25 (17.86%) Max=6.00 
5yrs or more 92 (65.71%) 
( 
IV Drug Users 
Yes (Current or Past) 56 (39.16%) Mean=0.39 Min=0.00 
No 87 (60.84%) S.D.=0.49 Max=l.00 
Note: S.D. =Standard Deviation, Min = Minimum Value, Max = Maximum Value. 
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Table 3: Mood Status of Patient Population (N=143) 
Mood Status N (0/o) 
Variables 
General Mental Health 
--
Mean=0.39 Min=0.00 
S.D.=0.49 Max=l.00 
Vitalitv 2 Ener&o: or -- Mean=0.39 Min=0.00 
Fatii:;ue S.D.=0.49 Max=l.00 
Note: S.D. =Standard Deviation, Min = Minimum Value, Max = Maximum Value. 
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Table 4: Physical Functioning Characteristics of Patient Population 
(N=143) 
Physical Functioning N (o/o) 
Variables 
Bodily l!ain in (!ast 4 
weeks 
None 37 (25.87%) Mean=2.88 
Very Mild 27 (18.88%) S.D.=1.49 
Mild 19 (13.29%) Min=l.00 
Moderate 41 (28.67%) Max=6.00 
Severe 14 (9.79%) 
Very Severe 5 (3.50%) 
Pain Interfering with 
normal work in (!ast 4 
weeks 
Not at all 47 (33.10%) Mean=2.31 
A little bit 41 (28.87%) S.D.=1.22 
Moderately 23 (16.20%) Min=l.00 
Quite a bit 25 (17.61%) Max=5.00 
Extremely 6 (4.23%) 
# of days in bed in the l!ast Mean=l.88 Min=0.00 
2 weeks 
--
S.D.=2.89 Max=20.00 
# of hos(!italizations in the Mean=O. 76 Min=l.00 
(!ast year 
--
S.D.=1.39 Max=8.00 
Note: S.D. =Standard Deviation, Min = Minimum Value, Max = Maximum Value. 
35 
Table 5: Emotional and Financial Support for Patient Population 
(N=143) 
Su_l!.l!_ort Variables NJ_O/o} Mean 
Emotional Su1rnort -- Mean=7.80 Min=0.00 
S.D.=8. 73 Max=60.00 
Financial Su1mort -- Mean=2.62 Min=0.00 
S.D.=3. 70 Max=22.00 
Note: S.D. = Standard Deviation, Min = Minimum Value, Max= Maximum Value. 
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Table 6: Multiple T-tests done on the IV of primary interest 
(IDUs/non-IDUs) and all other continuous IVs (N=143). 
Continuous Mean Mean p 
IVs _{ID_!J)_ _(Non-ID_ID_ Value 
Age (continuous) 41.00 37.97 0.01* 
Yrs. of Education 11.39 12.38 0.04* 
(continuous) 
# In Household 13.04 6.76 NS 
(continuous) 
General Mental Health 34.82 28.39 0.01* 
(continuous) 
Vitality, Energy or 37.79 35.50 NS 
Fatigue 
(continuous) 
# Days in Bed in past 2 2.37 1.60 NS 
weeks (continuous) 
# Hospitalizations in 0.76 0.76 NS 
past year (continuous) 
Emotional Support 16.57 16.83 NS 
(continuous) 
Financial Support 17.80 16.14 NS 
(continuous) 
Note: a =0.05, *]:>_value is significant, NS = Non Significant. 
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Table 7: Multiple Chi-Square Tests done on the IV of primary 
interest (IDUs/non-IDUs) and all other dichotomous IVs (N=143). 
Dichotomous mu Non-IDU p 
IVs % o/o Value 
Sex 
Male 65.45 74.71 NS 
Female 34.55 25.29 
Current Health Status 
Fair-Poor 51.79 27.59 0.01 * 
Excellent-Good 48.21 72.41 
Race 
Non-Whites 82.35 50.60 0.01* 
Whites 17.65 49.40 
Annual Income 
<$15,000 82.35 50.60 0.00* 
$15,000+ 17.65 49.40 
Insurance 
None 80.36 82.76 NS 
Some 19.64 17.24 
T-Cell Count 
>200 50.00 59.77 NS 
</= 200 50.00 40.23 
Duration since HIV + 
<5 years 23.64 41.18 0.03* 
5+ _years 76.36 58.82 
Bodily Pain in ~ast 4 weeks 
None 46.43 65.52 0.02* 
Ve_!Y Mild-V ~Severe 53.57 34.48 
Pain Interferina:; with normal 
work in ~ast 4 weeks 
Not At All 49.09 70.11 0.01 * 
A Little Bit-Extreme!r_ 50.91 29.89 
Note: a.=0.05, *p value is significant, NS = Non Significant. 
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Table 8: Multiple T-tests using the IV of Primary Interest (IDU/non-
IDU) as the Grouping Variable (N=143) 
Compliance Mean Mean p 
Variable (ID_ID_ fil_on-ID_ID_ Value 
Temptation to 7.54 6.78 0.28 
Skip Medication (NS) 
due to Side Effects 
Temptation to 5.95 5.98 0.96 
Skip Medication (NS) 
due to Lack of 
Support 
Temptation to 6.32 5.78 0.36 
Skip Medication (NS) 
when Feeling 
Good 
Temptation to 19.80 18.54 0.46 
Skip Medication (NS) 
on Total Scale 
Percent of Doses 1.56 2.19 0.41 
Missed in the Past (NS) 
Week 
Percent of Doses 2.85 4.41 0.08 
Missed in the Past (NS) 
Month 
Percent of Doses 2.87 3.52 0.41 
Missed in the Past (NS) 
Three Months 
Note: a=0.05, NS = Non Sigt1_ificant. 
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Table 9: Analysis of Covariance for the Temptation to skip 
medication due to side effects scale among IDUs and Non-IDUs. 
Covariates ID Us Non-ID Us 
Mean N Mean N Rz F p 
Age (continuous) 7.54 56 6.78 87 0.045814 2.43 NS 
Current Health 7.54 56 6.78 87 0.060960 0.24 NS 
Status (O= fair-poor, 
1 =excellent-good) 
Race (O= non- 7.60 55 6.78 87 0.023885 0.68 NS 
whites, 1 =whites) 
#Of Years of 7.54 56 6.81 86 0.018254 0.62 NS 
Education 
(continuous) 
Annual Income 7.35 51 6.76 83 0.009726 0.33 NS 
(O= <$15,000, 1 = 
$15,000+) 
Duration since HIV 7.36 55 6.81 85 0.004798 0.64 NS 
positive (O= <5 
years, 1 = 5+ years) 
General Mental 7.45 51 6.65 82 0.048265 0.37 NS 
Health (continuous) 
Pain Interfering 7.60 55 6.78 87 0.011549 1.11 NS 
with Normal Work 
in past 4 weeks 
(O= not at all, 1 = a 
little bit-extremehl 
Bodily Pain in past 7.54 56 6.78 87 0.012934 0.86 NS 
4 weeks (O=none, 
1 =very mild-very 
severe) 
Note: a=0.05, NS= Non S!.g_nificant. 
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Table 10: Analysis of Covariance for the Temptation to skip 
medication due to lack of social support scale among ID Us and Non-
IDUs. 
Covariates ID Us Non-ID Us 
Mean N Mean N R--z- F p 
Age (continuous) 5.95 56 5.98 87 0.021847 0.09 NS 
Current Health 5.95 56 5.98 87 0.001328 0.02 NS 
Status (O= fair-poor, 
1 = excellent-good) 
Race (O= non- 5.98 55 5.98 87 0.005653 0.04 NS 
whites, 1 =whites) 
#Of Years of 5.95 56 6.00 86 0.001161 0.02 NS 
Education 
(continuous) 
Annual Income 5.80 51 6.17 83 0.026101 1.23 NS 
(O= <$15,000, 1 = 
$15,000+) 
Duration since HIV 5.69 55 5.93 85 0.005065 0.06 NS 
positive (O= <5 
years, 1 = 5+ years) 
General Mental 5.76 51 5.77 82 0.039200 0.29 NS 
Health (continuous) 
Pain Interfering 5.98 55 5.98 87 0.008647 0.06 NS 
with Normal Work 
in past 4 weeks 
(O= not at all, 1 = a 
little bit-extreme!Y2_ 
Bodily Pain in past 5.95 56 5.98 87 0.002338 0.00 NS 
4 weeks (O=none, 
1 =very mild-very 
severe) 
Note: a.=0.05, NS= Non Significant. 
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Table 11: Analysis of Covariance for the Temptation to skip 
medication when feeling good scale among IDUs and Non-IDUs. 
Covariates ID Us Non-ID Us 
Mean N Mean N R-r F p 
Age (continuous) 6.32 56 5.78 87 0.023603 1.50 NS 
Current Health 6.32 56 5.78 87 0.044591 0.16 NS 
Status (O= fair-poor, 
1 = excellent-good) 
Race (O= non- 6.36 55 5.78 87 0.070018 0.07 NS 
whites, 1 =whites) 
#Of Years of 6.32 56 5.79 86 0.012592 0.48 NS 
Education 
(continuous) 
Annual Income 6.39 51 5.90 83 0.021621 0.09 NS 
(O= <$15,000, 1 = 
$15,000+) 
Duration since HIV 6.20 55 5.84 85 0.004098 0.29 NS 
positive (O= <5 
years, 1 = 5+ years) 
General Mental 6.22 51 5.70 82 0.016265 0.33 NS 
Health (continuous) 
Pain Interfering 6.36 55 5.78 87 0.007007 0.97 NS 
with Normal Work 
in past 4 weeks 
(O= not at all, 1 = a 
little bit-extreme!Yl_ 
Bodily Pain in past 6.32 56 5.78 87 0.005999 0.83 NS 
4 weeks (O=none, 
1 =very mild-very 
severe) 
Note: a.=0.05, NS= Non Significant. 
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Table 12: Analysis of Covariance for the Temptation to skip 
medication Total scale among IDUs and Non-IDUs. 
Covariates ID Us Non-IDUs 
Mean N Mean N R--z F p 
Age (continuous) 19.80 56 18.54 87 0.036661 1.37 NS 
Current Health 19.80 56 18.54 87 0.034371 0.08 NS 
Status (O= fair-poor, 
1 =excellent-good) 
Race (O= non- 19.95 55 18.54 87 0.031563 0.12 NS 
whites, 1 =whites) 
#Of Years of 19.80 56 18.60 86 0.010375 0.25 NS 
Education 
(continuous) 
Annual Income 19.55 51 18.83 83 0.018232 0.01 NS 
(O= <$15,000, l= 
$15,000+) 
Duration since HIV 19.26 55 18.58 85 0.001352 0.18 NS 
positive (O= <5 
years, 1 = 5+ years) 
General Mental 19.43 51 18.11 82 0.041215 0.07 NS 
Health (continuous) 
Pain Interfering 19.95 55 18.54 87 0.005335 0.74 NS 
with Normal Work 
in past 4 weeks 
(O= not at all, 1 = a 
little bit-extreme!tl 
Bodily Pain in past 19.80 56 18.54 87 0.003949 0.51 NS 
4 weeks (O=none, 
1 =very mild-very 
severe) 
Note: a=0.05, NS= Non Significant. 
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Table 13: Analysis of Covariance for the percent of doses missed 
during the past week among IDUs and Non-IDUs. 
Covariates ID Us Non-IDUs 
Mean N Mean N RT F p 
Age (continuous) 1.56 54 2.19 85 0.004416 0.58 NS 
Current Health 1.56 54 2.19 85 0.004419 0.58 NS 
Status (O= fair-poor, 
1 =excellent-good) 
Race (O= non- 1.58 53 2.19 85 0.006196 0.34 NS 
whites, 1 =whites) 
#Of Years of 1.56 54 1.99 84 0.004230 0.19 NS 
Education 
(continuous) 
Annual Income 1.71 49 2.30 81 0.017280 0.03 NS 
(O= <$15,000, 1= 
$15,000+) 
Duration since IDV 1.58 53 2.24 83 0.004830 0.65 NS 
positive (O= <5 
years, 1 = 5+ years) 
General Mental 1.47 49 2.26 80 0.008403 0.62 NS 
Health (continuous) 
Pain Interfering 1.58 53 2.19 85 0.009953 0.27 NS 
with Normal Work 
in past 4 weeks 
(O= not at all, 1 = a 
little bit-extreme!Y2_ 
Bodily Pain in past 1.56 54 2.19 85 0.011444 0.31 NS 
4 weeks (O=none, 
1 =very mild-very 
severe) 
Note: a =0.05, NS= Non Significant. 
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Table 14: Analysis of Covariance for the percent of doses missed 
during the past one month among IDUs and Non-IDUs. 
Covariates ID Us Non-IDUs 
Mean N Mean N Rz F p 
Age (continuous) 2.85 54 4.41 85 0.020528 2.84 NS 
Current Health 2.85 54 4.41 85 0.020607 2.20 NS 
Status (O= fair-poor, 
1 = excellent-good) 
Race (O= non- 2.74 53 4.41 85 0.030121 3.83 NS 
whites, 1 =whites) 
#Of Years of 2.85 54 4.38 84 0.027893 3.27 NS 
Education 
(continuous) 
Annual Income 2.88 49 4.47 81 0.019202 2.17 NS 
(O= <$15,000, 1= 
$15,000+) 
Duration since HIV 2.91 53 4.52 83 0.020337 2.69 NS 
positive (O= <5 
years, 1 = 5+ years) 
General Mental 2.86 49 4.48 80 0.029402 3.36 NS 
Health (continuous) 
Pain Interfering 2.91 53 4.41 85 0.036632 3.58 NS 
with Normal Work 
in past 4 weeks 
(O= not at all, 1 = a 
little bit-extremely) 
Bodily Pain in past 2.85 54 4.41 85 0.020377 2.83 NS 
4 weeks (O=none, 
1 =very mild-very 
severe) 
Note: a =0.05, NS= Non S!g_nificant. 
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Table 15: Analysis of Covariance for the percent of doses missed 
during the past three months among IDUs and Non-IDUs. 
Covariates ID Us Non-ID Us 
Mean N Mean N R~ F p 
Age (continuous) 2.87 54 3.52 86 0.004492 0.56 NS 
Current Health 2.87 54 3.52 86 0.006393 0.42 NS 
Status (O= fair-poor, 
1 =excellent-good) 
Race (O= non- 2.79 53 3.52 86 0.022040 0.25 NS 
whites, 1 =whites) 
#Of Years of 2.87 54 3.53 85 0.009745 0.35 NS 
Education 
(continuous) 
Annual Income 2.88 49 3.50 82 0.009106 0.90 NS 
(O= <$15,000, 1 = 
$15,000+) 
Duration since HIV 2.92 53 3.61 84 0.005003 0.67 NS 
positive (O= <5 
years, 1 = 5+ years) 
General Mental 2.84 49 3.65 81 0.007557 0.69 NS 
Health (continuous) 
Pain Interfering 2.92 53 3.52 86 0.003960 0.54 NS 
with Normal Work 
in past 4 weeks 
(O= not at all, 1 = a 
little bit-extremelY}_ 
Bodily Pain in past 2.87 54 3.52 86 0.004662 0.64 NS 
4 weeks (O=none, 
1 =very mild-very 
severe) 
Note: a=0.05, NS= Non S!.g_nificant. 
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Table 17: Analysis of Covariance for the Full Model using all the 
independent variables as covariates versus IDU/Non-IDU 
Dependent ID Us Non-ID Us 
Variables 
Mean N Mean N R--z- F p 
Temptation to Skip 7.88 17 7.32 34 0.384356 1.11 NS 
Medication due to 
Side Effects 
Temptation to Skip 6.12 17 6.59 34 0.571710 2.37 NS 
Medication due to 
Lack of Support 
Temptation to Skip 6.47 17 6.18 34 0.486722 1.69 NS 
Medication when 
Feeling Good 
Temptation to Skip 20.47 17 20.09 34 0.474725 1.61 NS 
Medication - Total 
Scale 
Percent of Doses 1.31 16 2.88 33 0.246919 0.55 NS 
Missed during past 
Week 
Percent of Doses 3.69 16 4.94 33 0.161825 0.32 NS 
Missed during past 
one month 
Percent of Doses 2.81 16 3.00 33 0.156837 0.32 NS 
Missed during past 
three months 
Note: a=0.05, NS= Non Significant. 
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( Managing Your Medications Questionnaire 
Please answer the following questions thoughifully and completely. This questionnaire is 
about how you think and feel about the HIV related medications that you are taking, and 
about the d([ferent strategies that people use to take their medications. It will take about 
45 minutes for you to fill this out. You may fill it out at home and mail it in or you may 
return it to this clinic. When you turn it in, we will give.you a gift certificate for $20 to 
thank youfor your participation. If you have the time to fill it out here, you may turn it i.n 
to the person who !'anded it to you, and receive your gift certificate now. 
CODE FOR THIS QUESTIONNAIRE: 
A) What are the first 3 letters of your mother's first name? 
Bl What ls your birth date? DDl[]DtOD 
mm dd yy 
SECTION I 
BACKGROUND WFORMATION 
The first section of this questionnaire asks about your background. 
- Please circle or fill in the correct response for each question. 
1. What ls your age? DD years 
2. What ls your gender? M F 
3. How would you describe your current health status? (Please check one answer) 
D Excellent 0 Very Good 0 Good D Fair D Poor 
4. Which of the followIIlg best describes your ethnic background? 
D White. non-Hispanic 0 Hispanic 0 African American 
D Native American 0 Asian D Other· 
5. How many years of education have you finished? DD 
6 . Do you currently work either part-time or full time? 
(1/1· 3) 
(1/4-9) 
(1/10-11) 
(1/12) 
(1/13) 
(1/14-15) 
(1/16) 
D Full-time 0 Part-time D I am not currently employed 
7 . Do you Uve by yourself or with other people? 
D By myself 0 Wlth others 
8. If you Uve with others. how many (besides you) are ln your hQusehold? OD 
9. If you Uve with others. what Is their relationship to you? (Check au Chat apply) 
D Husband or wife 0 Grandparents 
D Intimate partner 0 Children under age 18 
D Other adults 18 or older 0 Children over age 18 
D Parents 
Unlucrs((y of Rhode Is land. C 1996 
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(1/17) 
(l/11H9) 
(1/20-261 
.,_ 
( 10. - Do you have any children? If so. how many? (If none. put OJ OD 
11 . Do any of your adult children live nearby (within a half hour drive)? 
0 Yes 0 No 0 Not applicable 
12. How many of your family or friends can you count on for emotional support? 00 
13. How many of your family or friends can you count on for financial help? 00 
14. How many of your fa~ or friends can you count on for physical assistance. 
or a place to stay? 0 U 
15. Do you feel confident that your family or friends will continue to help you with 
your everyday needs? · 
0 Very confident . 
0 Fairly confident 
0 Somewhat confident 
0 Less than somewhat confident 
0 Not at all confident 
(1/27·26) 
(1/29) 
(1/30·31) 
(1/32·33) 
(l/3'4·35) 
(1/36) 
16. If you were to need more help with every day needs. do you feel confident that your family or 
friends could provide it? (l/37J 
D Very confident· 
D Fairly confident 
0 Somewhat confident 
0 Less than somewhat confident 
0 Notatallconfiden~ 
17. How many of your family & frtends have you told about your HIV infection? 
0 None 0 Less than half 0 .About half 0 More than half 0 All 
18. What type of health msurance coverage do you currently have? 
D NONE 
0 BlueCross 
0 Ocean State 
0 RIGHA 
0 HCHP 
0 Other private Insurer 
0 HMO 
0 Medicaid 
0 Medicare 
0 Other 
19. Which of the following best estimates your total (family) income during the 
past 12 months? 
0 Less than $15.000 
0 $15.000 to $24.000 
0 $25,000 to $34,000 
D $35.ooo to $44.ooo 
0 45.000 or more 
20. About how far do you live from this treatment center? 
0 Within walking distance 
0 Within a ten minute drive or less 
0 Within a twenty minute drive or less 
0 Within a thirty minute drive 
O More than thirty minutes away 
Unlucrslly of llhode Island. 0/99G 
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(1/38) 
(1/39-46) 
(1/49) 
(l/50) 
. -
21. When you have questions about medications for your HIV Infection. who do you 
usually ask? (Please check a!l !11Cll apply) 
0 Pharmacist 0 Other persons with Hrv lnfecUon 
0 Physician 0 Famlly members 
0 Social Worker 0 Friends 
0 Nurse 0 Other; please specify------------
(1/51·58) 
(1/59 · 76) 
22. Which health care provider ls most helpful lo you In laking your medications as directed? (1/791 
0 Nurse 
D Pharmacist 
D Physician 
0 Social Worker 
0 Other; please specify 1211-201 
23. Is there someone living With you or clo:>e to you who helps or reminds you to take your 
medications on time? 121211 
D Yes D No 
24. How much bodily pain have you had during the past four weeks? (2/22) 
0 None 0 Moderate 
0 Very mild 0 Severe 
. 0 Mild 0 Very Severe 
25. During the past 4 weeks. how much did pain interfere with your normal work (including both 
work outside the home and housework)? (2/231 
0 Not at all 0 A little bit D Moderately 0 Quite a bit D Extremely 
26. During the past two weeks. how many days did you stay in bed all or most 
of the day? DD 
27. How many times have you been hospitalized in the past year? (If none. put OJ 0 0 
(2/24-25) 
(2/26-27) 
28. These questions are about how you feel and how things have been with you during the past 4 
weeks. · 
For each question. please gioe the one answer that comes closest to the way you have beenf eeling. 
How much of the time during the past 4 weeks ... 
NONE 
OF THE 
TIME 
A.LrrnL 
BIT OF THE 
TIME 
55 
SOME 
OF THE 
TIME 
A.GOOD 
BIT OF THE 
TIME 
MOST 
OF THE 
TIME 
/U..L 
OF THE 
TIME 
(2/30) 
(2/31) 
(2/32) 
(2/33) 
(2/34) 
(2/35) 
(2/36) 
. ~ · - -· .. : . . 
29. How long ago were you diagnosed as HCV positive? 
0 Less.than a month 
0 One to six months . 
O More than six months. but less than a year 
30. How do you think you got your HCV infection? 
Please check all that apply 
0 Injection (IV) drug use 
0 Heterosexual contact 
0 Homosexual contact 
0 Blood transfuslon 
0 Other. 
0 1to2 years 
0 3 to 4years 
0 5 years or more 
31. What was your T cell count (CD4 count) the last tlme you were tested? 
0 Greater than .500 0 201-500 0 50-200 0 Less than 50 
Unlvers((y of Rhode: Island. 0 I 99G 
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(2/37) 
(2/38-42) 
(2/43~) 
(2/63) 
( 
. = · - ··.~: .; · 
SECTION II 
MEDICATION HISTORY 
WHICH OF THE FOLLOWING MEDICATIONS ARE YOU TAIGNG NOW? 
..... PLEASE CHECK ALL TIIAT APPLY: 
0 Indinavir (Crtxivan®) 
(2/64-771 
0 AZf (Retrovir®, zidovudlne) 
0 DDI (Vldex®. dldanoslne) 
0 DOC (Hivid®, zalcltablne) 
0 D4T (Zerlt®. stavudlne) 
0 Trtmethoprtm ()r Sulfamethoxazole (Bactrtm®. Septra®) 
0 Clartthromycln (Blax1n@) 
0 3TC (Eplvir®, lamlvUdlne) 
0 Saqulnavir (Invirase®) 
0 Rltonavir (Norvir®) 
0 Dapsone 
0 F1uconazole (Dlfiucan®) 
0 Itraconazole (Sporanox®) 
0 Rlfabutln (Mycobutln®) 
0 Other.------------
We would like to ask you about each medicine that you are currently taking. Pleasefill out 
the following 2 page medicationformfor each medicine that you checked on the above list. 
If you are CWTently taJcing 1 medicalion. f il.l out 2 pages_ 
If you are currently taJcing 2 1T1-edi.cations, Jill out 4 pages. 
If you are cwrently taJcing 3 medico Hons, Jill out 6 pages_ 
If you are CWTently taJcing more than 3 medications, please fiU out 6 pages and additional 
pages in the Supplement at the end of this questionnaire. 
Pease go to page 12 after you have filled out these medicati.onforms_ . 
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MEDICATION #1 
MEDICINE NAME. ________ ___ _ _ _ _ _ _ 
L Tilis medicine Is for: 
0 HIV Infection 
0 To treat or prevent PCP (Pneumocystis ca.rin!i pneumonia) 
0 To treat or prevent MAI (Mycobactertum avium complex) Infection 
0 To treat or prevent fungal Infections (Candida or ·thrush·) 
D Other:------------0 Don'tlmow 
2. How often do you take this medicine? 
0 Two times a week 
0 Three times a week 
0 Every other day 
D Once a day 
0 Two times a day 
0 Three times a day 
0 Four times a day 
D Five times a day 
D Other:--------
3. How long have you been taking this medication? 
Less than 1 month 
1to3 months 
4 to 6 months 
__ 6 months to 1 year 
__ 1 to 2 years 
__ more than 2 years 
4. During the last 3 months, have you ever stopped taking this medication because you 
felt better? 
DYES D NO 
(3/1-20) 
(3/21) 
(3/22-41) 
(3/42-50) 
(3/Sl-70) 
(3/71) 
(3/nl 
5. DW"ing the last 3 months, have you ever stopped taking this medication because you felt 
worse? (3/73) 
DYES D NO 
6. DW"ing the last 3 months, have you ever forgotten to take this medication? (3/74) 
DYES D NO 
7. DW"ing the last 3 months, have you at times been careless about taking this medication? (3/751 
DYES D NO 
8. DW"ing the last 3 months, have you ever taken less of this medicine than your doctor 
prescribed because you felt better? (3/761 
DYES D NO 
9 . DW"ing the last 3 months, have you ever taken less of this medicine than your doctor 
prescribed because you felt worse? (3/771 
DYES D NO 
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MEDICATION #2 
MEDICINE NAME _____________ _ 
l. This medicine Is for: 
0 HIV Infection 
0 To treat or prevent PCP (PneWTIDqJstls cartnU pnewrumia} 
0 To treat or prevent MAI (Mycobactertum avium complex) Infection 
0 To treat or prevent fungal Infections (Candida or ·tiuush·) 
D Other.------------0 Don't know 
2. How often do you take this medicine? 
0 Two times a week 
0 Three times a week 
0 Every other day 
D Once a day 
0 Two times a day 
0 Three times a day 
0 Four times a day 
0 Five times a day 
0 Other.---------
3. How long have you been taldng this medication? 
Less than 1 month __ 6 monfus to 1 year 
1 to 3 months __ 1 to 2 years 
4 to 6 monfus __ more than 2 years 
4. During the last 3 months, have you ever stopped taking this m edication because you 
felt better? 
0 YES 0 NO 
(S/1 -20) 
(S/21) 
(S/2:2-41) 
(S/42-50) 
(5/51-70) 
(5/71) 
(5/72) 
5. During the last 3 months, have you ever stopped taking this medication because you felt 
worse? (5/731 
0 YES 0 NO 
6. During the last 3 months, have you ever forgotten to take this medication? 
0 YES 0 NO 
(5/74) 
7 . During the last 3 months, have you at times been careless about taking this medication? (5/75l 
0 YES 0 NO 
8. During the last 3 months, ·have you ever taken less of this medicine than your doctor 
prescribed because you felt better? (5/761 
0 YES 0 NO 
9. During the last 3 months, have you ever taken less of this medicine than your doctor 
prescribed beca use you felt worse? (5/77) 
0 YES 0 NO 
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10. Since you began taking this medication. have you ever purposely: 
al taken more of the medicine than your physician prescribed? 
bl taken less of the medicine than your physician prescribed? 
cl discontinued or stopped taking your rnedicaUon? 
!lJE§_, 
YES 
D 
D 
D 
NO 
D 
0 
0 
15/78) 
(5/79) 
(5/80) 
11. a) How many times have you discontinued your medication for more than 3 days? (6/l-21 
bl What were your n;asons for discontinuing your medication? 
Please check all that apply 
0 My doctor recommended it 
0 Too many side effects 
0 I didn't want to be reminded of my illness 
0 Problems with insurance coverage 
0 I didn't think it was working 
0 Other.----------
(6/3·81 
(6/9-28) 
12. Sometimes it ls difficult to take prescribed medicine all the time. During the past week, how 
many times did-you miss a dose of MEDICATION 2? (6/29-3-0l 
13. During the past month, about how many times did you miss a dose of MEDICATIO~ 2? 
(6/31-32: .. 
14. During the past three months, about how many times did you miss a dose MEDICATION 2? 
(6/33-34) 
15. Please check any side cffect(s) you are having that you believe are caused by this medicine: 
(4/35-50) 
Onausea 
D dizziness 
Ovomlting 
Oabdomlnal pain 
0diarrhea 
Oother: 
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0 shortness of breath 
0 muscle aches 
0fatlgue 
0 tingling in hands/feet 
Onumbness in hands/feet 
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0 headaches 
0 anxiety/worry 
0 depression 
. 0 rash 
0 sensitivity to sun 
(6/51-70) 
.  
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MEDICATION #3 
M EDICINE NAME _________ ____ _ 
l. This medicine is for: 
0 HIV infection 
0 To treat or prevent PCP (Pneumocystis cartnll pneumonia) 
0 To treat or prevent MAI (Mycobactertum avium complex) infection 
0 To treat or prevent fungal infections (Candida or ·thrush·) 
0 Other:------- ------0 Don't know 
2 . How often do you take this medicine? 
0 1Wo times a week 
0 Three times a week 
0 Every other day 
0 Once a day 
0 1Wo times a day 
0 Three times a day 
0 Four times a day 
0 Five times a day 
0 Other:---------
(7 / l-20) 
(7/21) 
(7/22-41) 
(7/42-50) 
(7/51-70) 
3 . How long have you been taking this medication? {7/711 
Less than 1 month __ 6 months to 1 year 
1 to 3 months __ 1 to 2 years 
4 to 6 months __ more than 2 years 
4. Dwing the last 3 months, have you ever stopped taking this medication because you 
felt better? C7ml 
0 YES D NO 
5. During the last 3 months, have you .ever stopped taking this medication because you felt 
worse? {7 /731 
0 YES D NO 
6. During the last 3 months, have you ever forgotten to take this medication? {7/74) 
0 YES D NO 
7. During the last 3 months, have you at times been careless about-_ taking this medication? (7/7'SJ 
0 YES D NO 
8. During the last 3 months, have you ever taken less of this medicine than your doctor 
prescribed because you felt better? {7/761 
0 YES D NO 
9 . During the last 3 months, have you ever taken less of this medicine than your doctor 
prescribed because you felt worse? (7 /TTJ 
0 YES D NO 
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10. Since you began taking this medication. have you ever purposely: 
YES 
a) taken more of the medicine than your physician prescribed? 0 
bl taken less of the medicine than your physician prescribed? 0 
c) discontinued or stopped taking your medication? 0 
~. 
NO 
0 
0 
0 
(7/78) 
(7/79) 
(7/80) 
11. a) How many times have you discontinued your medication for more than 3 days? (8/1-2) 
bl What were your reasons for discontinuing your medication? 
Please check all that apply 
0 My doctor recommended it 
0 Too many side effects 
0 I didn•t want to be reminded of my lllness 
0 Problems with insurance coverage 
0 I didn•t think it was working 
0 Other.----------
(8/3-8) 
(8/9-28) 
12. Sometimes It ls difficult to take prescribed medicine all the time. During: the past week, how 
many times did you miss a dose of MEDICATION 3? (8/29-30) 
13. During the past month, about how many times did you miss a dose of MEDICATION 3?. 
(8/31-32) 
14. During the past three months, about how many times did you miss a dose MEDICATION 3? 
(8/33-34) 
· 15. Please check any side effect(s) you are having that you believe are caused by this medicine: 
(8/35-50) 
Onausea 
0d1.zz1ness 
Ovomitlng 
Oabdominal pain 
0d1arrhea 
Oother: 
Unlucrslty of Rhode Island. O 1996 
0 shortness of breath 
0 muscle aches 
Oraugue 
0 tingling in hands/feet 
Dnumbness in hands/feet 
63 
0 headaches 
0 anxiety/worry 
0 depression 
0 rash 
· 0 sensitivity to sun 
(8/51-70) 
( 
.= ·~~--· · . . . 
Next, we would like to ask about your attitudes toward taking each of three dW"erent kinds 
of medications. Please fill out each of the following sections ONLY if you haue taken or are 
currently taking any of the medications listed in each secfion. 
SECTION m: ANTIVIRAL MEDICATIONS ••••.•••• .Please go to page 13 . • 
(AZT (Relro1.11T@. zldo1.1ud.ine), DDI (V&dex®, didanoslne), DDC (Hlvld®, zalcltablne), 
D4T (Zerit®. stavudlne). or 3TC (Eplvil®. lamivudine)/ 
SECTION IV: ANTI-INFECTIVE MEDICATIONS ••••••••• .Please go to page 21. 
(Trimethoprim or Sulfamethoxazole (Bactrim®. Septra®.J. Clarithromycin (Biaxin®J. 
Fluconazole (Dijlucan®), Itra.conazole (Sporanox.®). or Rif abutin (Mycobutin®)J 
SECTION V: PR07EASE INHIBITORS ••••••••• .Please go to page 29 • 
(Sa.quinavir (Invirase®). Ritonavir (Norvil®), or Indinavir (Crixivan®)J 
Please go to page ~3 after you have completed these medication sections. 
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SECTION ID 
ANTIVIRAL MEDICATIONS 
REMINDER: FILL OUT TfilS SECTION IF YOU HAVE EVER TAKEN ANY OF THESE ANTIVIRAL 
MEDICATIONS: AZT (Retrovir®, zidovudine}, DDI (Videx®, didanosine}, DDC (I-livid®, 
zalcitabine}, D4T (Zent®, stavudine}, or 3TC (Epivir®, lamivudine}. If not, skip to page 24. 
If you are taking more than one antiviral medication NOW. please answer these 
questions for the medicine that ts most dlfficu.Ufor .you to take, andjill in the 
name of that medicine here (9/1-201 
If you have discontinued your antiviral medication. please answer these ques· 
tions for the medicine that you took most recently. andfiU in the name of that 
medicine here (9/21-40l 
Taking medications as directed (the prescribed amount taken at the right time) is not alway~ easy. 
At one time or another most people simply forget to take a dose of their medication. and sometimes 
.people discontinue taking their medications for a while. The following Is a llst of possible advan-
"tages and disadvantages of taking antiviral medications as directed . 
For each numbered statement. please mark one box with an ·x:- to rate HOW .IMPORTANT 
that statement ts to you when you are thinking about whether to take your anliuirol 
medication as directed. 
ExnEMELY IMPORTANT ;I 
2. Taking my antiviral medication as directed may delay some 
symptoms of HIV infection. 
4. Taking too many medications may not be good for my health. 
6. Taking all of my antiviral medication as directed Is too expensive. 
8. Taking my antiviral medication as directed may make up for my 
unhealthy habits. 
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VERY IMPORTANT 4 
0 0 0 0 
0 0 0 0 
0 0 0 0 
0 0 0 0 
0 0 0 0 
D 0 D 0 
D 0 D 0 
0 
D 
0 
0 
0 
0 
D 
(9/42) 
(9/43) 
(9/44) 
(9/45) 
(9/46) 
(9/47) 
(9/48) 
_.-:·· 
. . ··-- ~: :". .. 
EXTREMELY lMPORTANT 15 
10. When I'm away from home or on vacation. taking my antiviral 
medication as directed ls difficult. 
12. Taking my antiviral medication as directed causes too many 
annoying side effects. 
14. I worry that taking.all the doses that are presi::rtbed might not be 
good for me. 
16. I worry that the antiviral medication Is doing more harm than 
good. 
18. It may be hard on my system. if I take my antlviiaI medication 
as directed. 
VERY IMPORTANT 4 
0 0 0 0 0 (9/49) 
0 0 0 0 0 (9/50) 
0 0 0 0 0 (9/51) 
0 0 0 0 0 (9/52) 
0 0 0 0 0 (9/53) 
0 0 0 0 0 (9/54) 
0 0 0 0 0 (9/561 
0 0 0 0 0 (9/57) 
DODOO (9/56) 
0 0 0 0 0 (9/59) 
20. Taking my antiviral medication as directed will help me feel better. D D D 0 D (9/601 
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Sometimes people take their medlcatlons as directed for n while, and then stop taking them 
for a while. 
- The following 2 questions are about how you are Lalcing your anliuiral medication RIGHT NOW. 
21. Do you consistently take your antiviral medication as directed? ("as directed" means takJng 
your medication at the right lime and taking the prescribed amounl) (9/61 ·801 
a. No, I do not. and I am not considering takJng my antiviral medication as directed. 
b. No, I do not. but I am considering taking my antiviral medication as directed. 
c. No. I do not. but I am planning to start takJng my anllviral medication as directed 
within the next month. 
__ d . Yes. I consistently take my antiviral medication as directed. 
I[ues . 
..... 22. How long have you been taking your antiviral medication as directed? (10/l) 
a. 0-3 months 
b. 4-6 months 
c. 6-12 months 
d. more than 12 months 
Now here arc some situations that might affect whether you take your antiviral medication 
for HIV Infection as directed. 
For.each situation. please ritark one box with an "X" to rate HOW TEMPTED you would be to skip your 
antiviral medication or talce a dose which is different from the one prescribed. 
24. When you are anxious about side effects. 
26. When you wonder whether you really need your medication. 
28. When you experience minor side effects. 
30. When your doctor doesn't seein Interested In whether you take 
your medication. 
32. When side effects are annoying. 
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EXTitEMELY 'IEMPTED 5 
VERY TEMPTED 4 
D D D D 0 
D D D D D 
D D D D 
D D 0 D D 
D D D D D 
(10/2) 
(10/3) 
(10/4) 
(IO/SJ 
(10/6) 
(10/71 
(10/6) 
(10/9) 
(I0/10) 
(I0/11) 
.. .. .,, .. ·- · 
. . 
EXTREMELY TEMPTED 6 
34. When your medical condition doesn't seem that bad. 
36. When It seems too complex: to keep track of all your medications. 
38. When your doctor doesn't explain why you need to take your 
medication. 
mawJ@Mif-0Jl!IW®MMM'*wMW 
40. When you aren•t sure If the med!c1ne· 1s really helping you. 
42. When you don•t understand why you need your medication. 
44. When your family or friends don•t seem concerned enough 
about your condition. 
-46. When your family or friends don't seem Interested In whether 
you take your medication. 
· 48. When your Insurance doesn•t cover the cost of your medication. 
50. When you worry that taking too many medications might be bad 
for your health. 
52. When you worry that the chemicals in the medication might 
harm or hurt your body. 
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VERY TEMPTED 4 
D 0 D D D 
D 0 D D D 
D 0 D D D 
D 0 D 0 D 
D 0 D D D 
DO D D D 
D 0 0 D D 
D D D D D 
D D D D D 
DD D D D 
D D D D D 
·D D D D D 
DO D D D 
D [j D D D 
DD DD D 
DO DD D 
DD DD D 
D 0 DO D 
DO DO D 
I 
(I0/12) 
(I0/13) 
(I0/14) 
(10/15) 
(I0/16) 
(10/17] 
(10/16) 
(10/19) 
(10/20) 
(10/21) 
(10/22) 
(10/23) 
(10/24) 
(10/25) 
(10/26) 
(10/271 
(l0/26) 
(I0/29) 
(I0/30) 
(10/31) 
I 
I 
The following statements represent some thoughts and experiences that people have when 
they are taking nntlvlral medications on a regular basts. Think about your thoughts and 
e xp e riences during the past month . 
~ For each nwnbered statement. please mark one box w ith an -x- to best describe HOW OFTEN that 
thoug ht occurs or has occurredfor you during lhe past month. 
VERY OFTEN IS 
OFTEK 4 
OCCASIONAi.LT 3 
RARELY 
54. I call my health care provider if I have questions about taking my 
antiviral medications. 
56. I reward myself when I take my antiviral medications as directed. 
58. When I am tempted to skip a dose of my antiviral medication. 
I remind myself about the importance of staying on schedule. 
60. I feel good about myself when I remember to take my antiviral 
medications as directed. 
62. I think that taking my antiviral medications as directed may 
provide knowledge to help others who have HN infection. 
2 
0 0 0 0 0 (10/321 
0 0 0 0 0 (10/33) 
0 0 0 0 0 (10/34) 
0 0 0 0 0 (10/35) 
0 o· D 0 .0 lt0/36) : 
0 D D 0 0 (10/37) 
·o D D 0 0 (10/381 
0 D 0 0 0 (10/39) 
D D D 0 0 (10/40) 
D D 0 0 0 1101411 
0 D 0 0 0 001421 
64. When taking my antiviral medications feels llke a hassle. I remind 0 0 0 0 0 (I0/431 
myself of all the benefits of continuing to take them ~egularly. 
.. 
D D D 0 D 001441 
66. When rm unable to take my antiviral medications as directed. D D 0 0 0 11014s1 
I'm disappointed In myself. 
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68. I think that taldng my antiviral medications as directed will help 
my family and friends by giving them hope. 
70. I talk to my health care provider before changing the way I take 
my antiViral medications. 
72. I build taking my antiViral medications into my schedule. 
74. When I am on vacation or away from home. I make special efforts 
to continue taking my antiviral medications as directed. 
76. I ·get upset with myself when I skip my antiviral .medications. 
78. When I plan my day. I make sure to include taking my antiviral 
medications. 
80. When it Is difficult to take my antiviral medications as directed. 
I remind myself that others. are counting on me. . 
82. I think that I am making a contribution to scientific knowledge 
about HIV by taking my antiviral medications as directed. 
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VERY OFTEN 6 
OFTEN 4 
3 
2 
0 D D D D (I0/46) 
0 D D 0 0 (I0/47) 
0 0 0 0 0 (I0/48) 
0 0 0 0 0 (I0/49) 
0 D 0 0 0 (I0/50) 
0 0 0 0 0 (I0/51) 
0 0 0 0 0 (I0/~21 
:. 
0 0 . 0 0 0 (10/53) 
0 0 0 0 q (Jo/541 
D D 0 D D (10/55) 
0 0 0 0 0 (I0/56) 
0 0 0 0 0 (10/57) 
0 0 0 0 0 (I0/58) 
D D D D 0 (10/59) 
0 0 0 DD (10/60) 
0 0 0 DO (I0/61) 
DO DO D (10/621 
( 
85. Emotional support from-others helps me take my antiviral 
medications as directed. 
VERY OFTEN 6 
OFTEN 4 
3 
2 
0 0 0 0 0 (10/631 
0 0 0 0 0 · (10/641 
0 0 0 0 0 . (10/65) 
87. I try to take my antiviral medications at the same time and place 0 0 0 0 0 (I0/66J 
so that I won't forget 
89. I use determination to help me stick to my regular 
medication-taking schedule. 
91. I tell myself and others that I will take my antiviral medications 
as dlrected. 
93. I have someone I can rely on to help me With my antiviral 
medication schedule. 
95. I avoid situations that make it difficult for me to remember to 
take my antiviral medications. 
97. I feel more responsible when I am taking my antiviral 
medications as directed. 
99 . I regula rly check my supply of pills. 
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0 0 0 0 0 (10/67) 
0 0 0 0 0 (10/681 
0 0 0 0 .o (10/69°; 
0 0 0 0 0 (I0/70) 
0 0 0 0 0 (I0/711 
0 0 0 0 0 uomi 
0 0 0 0 0 (IO/T.ll 
0 0 0 0 0 (I0/741 
0 0 0 0 0 (I0/75) 
0 0 0 0 0 (I0/76) 
0 0 0 0 0 (\0/77) 
o o o o· o c1011a1 
( 
... ;_ . __ -·· . . ;.":..~ ·.,::- -
101. I feel that my health car_e provider really helps me take my 
antiviral medications a.S directed. 
103. I feel that rve earned my health care provider's approval when 
I take my antiviral medications as directed. 
105. When I get depressed. I make special efforts to continue 
taking my antiviral medications as directed. 
107. When I think of the· times when I didn't care about taking 
my antiviral medications. I feel angry with myself. · 
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0 
0 
0 
0 
0 
0 
0 
0 
.. 0 
VERY OFTEN 
OFTEN 
" 
3 
2 
0 D 0 
0 D 0 
0 D 0 
0 D 0 
0 D 0 
0 D 0 
0 D 0 
0 D 0 
D D 0 
6 
D (l0/79) 
D (10/80) 
0 (l l/l) 
0 
_, 
(ll/2) 
D (ll/3) 
0 (ll/4) 
D (ll/5) 
D (l l/6) 
D (l l/71 
SECTION IV 
ANTI-INFECTIVE MEDICATIONS 
REMINDER: FILL OUT THIS SECTION IF YOU HAVE EVER TAKEN ANY OF THESE MEDICINES 
TO HELJ> PREVENT PNEUMONIA OR INFECTION: 
Trimethoprim or Sulfamethoxazole (Bactrim®, Septra®,), Clarithromycin (Biaxin®), 
Fluconazole (Diflucan®), Itraconazole (Sporanox®}, or Rif abutin (Mycobutin®). 
If not. skip to page 34 • 
..... 1j you are taking more than one anti-infective medication NOW. please answer these questions 
for the medicine that ls mo~ d!ffiru.ltfor you to tal<e. and fill in the name of that medicine here 
(ll/8·271 
- !J you have discontinued your antHnfective medication. please answer these questions 
for the medicine that you took most recently, andf tU in the name of that medicine here 
(11/28-47) 
Taking medications as directed (the prescribed amount taken at the light time) Is not always easy. 
At one time or another most people simply f9rget to take a dose of their medication. and sometimes 
people discontinue taking their medications for a while. Tue following ls a list of poSslble advan-
tages and disadvantages of taking anti-infective medications as directed . 
..... For each numbered statement. please mark one box with an ·r to rate HOW IMPORTANT that 
statement is to you when you are thinking about whether to tal<e your 011ti·in[ective medication 
as directed. 
EXTREMELY IMPoRTANT 5 
VERY IMPORTANT 4 
0 0 0 0 0 (1 l/4S) 
' . 
· · .. :. · 2. Taking my anti-Infective medication as directed may delay some 0 0 0 0 0 (ll/49) 
symptoms of mv infection. 
4. Taldng too many medications may not be good for my health. 
6. Taking all of my anti-Infective medication as directed is too 
expensive. 
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0 
0 
0 
0 
0 
0 0 
0 0 
0 0 
0 0 
-0 0 
0 0 (ll/50) 
0 D (11/Sl) 
0 0 (11/521 
0 0 (11/53) 
0 0 (11/S-ll 
EXTR£MELY lMPORTANT 5 
VERY lMPORTANT 4 
MODERATELY lMPORTANT 3 
NOT lMPORTANT l 
DODOO 
9. When I take my antl-lnfectlve medlcatlon as directed. I feel more 
responsible. 
11. When I take my antl-lnfective medlcatlon as directed, It makes 
me feel depressed about having HIV Infection. 
13. Taking my anti-infective medication as directed will slow down 
this illness. 
· 15. Taking my antl-lnfective medication as directed gives me hope. 
17. Taking my antI~lnfective medicatlon as directed may help me 
stay well longer. 
19. I worry that people will know that rm sick if I take my anti-
infectlve rnedlcatlon as directed. 
0 
0 
D 
0 
0 
0 
0 
D 
0 
D 
0 
0 D 0 0 
0 D 0 0 
D D 0 0 
0 D 0 D 
0 D D 0 
0 D 0 0 
0 D D D 
0 D 0 D 
0 D D D 
D D D D 
D DO 0 
ll 1/55) 
ll 1/561 
ll 1/57) 
(11/581 
(ll/59) 
(11/60) 
(11/611' . . 
(11/621 
(11/631 
(11/641 
(ll/65) 
(11/661 
0 0 DO 0 (ll/67] 
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Sometlmes people take their medications as directed for a whllc. and then stop taking them 
for a while . 
...... ThefoUowing 2 questions are about how you are taking your anti-infective medication RIGHT 
NOW. 
21. Do you consistently take your anti-Infective medication as directed? ("as directed" means taking 
your medication at the right time and taking the prescrl~d amount) ll l/681 
a. No. I do not. and I am not considering taking my anti-Infective medication as directed. 
b. No, I do not. but I am considering taking my anti-Infective medication as directed. 
c. No, I do not. but~r am planning to start taking my anti-Infective medication as 
directed within the next month. 
d. Yes. I consistently take my anti-infective medication as directed. 
If yes • 
...... 22. How long have you been taking your anti-infective medication as directed? (11/691 
a. 0-3 months 
b. 4-6 months 
c. 6-12 months 
d. more than 12 months 
Now here are some situations that might affect whether you take your anti-infective medication for 
HIV Infection as directed . 
...... For each situation. please mark; one box with an "X" to rate HOW TEMPTED you would be to 
skip your anti-fnfectiue medication or talce a dDse which is different from the one prescribed.. 
l EXTREMELY TEMPTED 5 
l VERY TEMPTED 4 
l MODERATELYTEMPTED 3 
lsUGHTLY TEMPTED 2 
r NOT TEMPTED l 
24. When you are anxious about side effects. 
26. When you wonder whether you really need your medleatlon. 
28. When you experience minor side effects. 
~~~~--~~,-·- ····-"··········'· ..... - .-~m ..... ~- .. ! 
30. When your doctor doesn't seem interested In whether you take 
your medication. 
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0 
0 
0 
D 
D 
0 
0 
0 
·0 0 
0 0 
0 0 
D 0 
D D 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 D 
D D 
0 tl 
0 0 
0 0 
(11/70) 
(ll/7ll 
(ll/72) 
lll/73) 
(11/74) 
(11/75) 
(11/76) 
(11/77) 
( 
·' 
EXTREMEL Y TEMPTED 5 
VERY TEMPTED 4 
0 0 0 0 0 
32. When side effects are annoying. 0 0 0 0 0 
0 0 0 0 0 
34. When your medical condition doesn't seem that bad. 0 0 0 0 0 
0 0 0 0 0 
36. When It seems too complex to keep track of all your medications. 0 0 0 0 0 
38. When your doctor doesn't explain why you need to take your 
medication. 
40. When you aren't sure If the medicine is really helping you. 
42. When you don't understand why you need your medication. 
44. When your family or friends don't seem concerned enough 
about your condition. 
46. When your family or friends don't seem Interested In whether 
you take your medication. 
48. When your insurance doesn't cover the cost of your medication. 
50. When you worry that taking too many medications might be bad 
for your health. 
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0 0 0 0 0 
0 0 D 0 0 
0 0 D 0 0 
0 0 D 0 0 
0 0 D 0 0 
D 0 0 0 0 
D 0 D 0 0 
D 0 D 0 D 
D 0 D 0 D 
D 0 DO D 
D 0 DO D 
D 0 DO D 
D 0 DO D 
DO DO D 
111/78) 
01/79) 
111/80) 
112/1) 
112/2) 
(12/3) 
(12/4) 
02/5) 
112/6) 
,. 
(12/7) 
(12/8) 
02/9) 
(12/10) 
(12/11) 
(12/12) 
(12/13) 
(12/14) 
(12/15) 
0 2/ 16) 
(12/17) 
EXTREMELY TEMPTED 5 
VERY TEMPTED 4 
MODERATELY TEMI'TED 3 
m?!~V'"~q{!.:~!fil~==W-.Wifff~r::~-~·"'~" '''*Will 0 0 0 0 0 (12/1s1 L~iit1mwa?i?Y~~~l$k,:J~~~-~ · tt."! ~ 
52. When you worry that the chemicals ln the medlcatlon might 0 0 0 0 0 (12/t9J 
harm or hurt your body. · 
The following statements represent some thoughts and experiences that people have when 
they are taking anti-Infective medications on a regular basis. Think about your thoughts ;nd 
experiences during the past month. 
_. For each numbered statement please mark one.box with an ·;x:- to best desaibe HOW OFTEN that 
thought occurs or has occurredfor you during the past month. 
VERT OFTEN Ii 
OFTEN 4 
OCCASIONALLY 3 
· RARELY 2 
NEVER 
DODOO (12/20) 
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VERY OF"TI!:N 5 
OFTEN 4 
OCCASIONAU.Y 3 
RARELY 2 
63. I do something special for myself when I take my anti-lnfectlve 
medications as directed. 
65. I tell myself that following a regular schedule will help me take my 
anti-infective medications as directed. 
67. I get upset when I hear about people Uke me who stop taking 
their anti-infective medications. 
69. I ask my health care provider for infonnatlon about my 
anti-Infective medications. 
71. Someone close to me reminds me to take my anti-Infective 
medications as directed. 
73. I use a pill organizer or timer to help me take my anti-Infective 
medications as directed. 
75. I encourage myself to stick to my regular medication sch~dule. 
77. I feel that when I take my anti-Infective medications as directed. 
I am a good role model for others. 
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0 0 0 0 0 (12/29) 
0 0 0 0 0 (12/30) 
0 0 0 0 0 (12/31) 
0 0 0 0 ·o (12/32) 
0 0 0 0 0 (12/33) 
D 0 0 0 D (12/34) 
D 0 0 0 D (12/35) 
D 0 0 0 D (12/36) 
0 D D D 0 (12/37) 
D D D 0 D (12/38) 
0 b D D D (12/39) 
0 D 0 DD (12/40) 
0 D DO 0 (12/41) 
D D DD D (12/42) 
D OD DD (12/43) 
0 0 DO 0 (12/44) 
r 
VERY OFTEN 6 
OFTEN 4 
OCCASIONALLY 3 
RARELY 2 
95. I avoid situations that make·lt difficult for me to remember to 
take my anti-Infective medications. 
97. I feel more responsible when I am taking my anti-Infective 
-medications as directed. 
99. I regularly check my supply of pills. 
101. I feel that my health care provider really helps me take my 
anti-Infective medications as directed. 
103. I feel that rve earned my health care provider's approval when 
I take my anti-Infective medications as directed. 
105. When I get depressed, I make special efforts to continue taking 
my anti-Infective medications as directed. 
107. When I think of the times when I didn't care about taking my 
anti-Infective medications. I feel angry with myself. 
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0 0 0 0 0 (12/61) 
0 0 0 0 0 (12/621 
0 0 0 0 0 (12/63) 
0 0 0 0 0 (12/64) 
0 0 0 0 0 (12/6SJ 
0 0 0 0 0 (12/66) 
0 0 0 0 0 (12/67) 
0 0 0 0 0 (12/68) 
0 0 0 0 0 (12/69) 
0 0 0 0 0 (12/70) 
0 0 0 D D (12/71) 
0 0 DD D (12/72) 
·o 0 DD 0 (12/73) 
0 0 D-D D (12/74) 
0 DD DD (12/75) 
" 
'. 
·· :· 
SECTIONV 
PROTEASE INHIBITOR MEDICATIONS 
REMINDER: FILL OUT THIS SECTION IF YOU HAVE EVER TAKEN ANY OF THESE PROTEASE 
INHIBITOR MEDICATIONS: Saquinauir (Inuirase®J, Ritonauir (Noroir®), or Indinauir 
(Crixiuan®}. I( not, skip to page 39. 
- If you are taJdng more than one protease Inhibitor medication NOW. please answer these 
questions for the medlc!ne that ls most dl.ffii;:ultfor you to take. andfiU ln the name of that 
medicine here (13/1-201 
- If you have discontinued your protease lnhibitor medication. please answer these 
questions for the medicine that you took most recently. and fill in the name of that medicine 
here (13/21-40) 
Taking medications as directed (the prescribed amount taken at the right time) ls not always easy. 
At one tlme or another most people simply forget to take a dose of their medication. ahd sometimes 
people discontinue taking their medlcatlons for a while. The following ls a list of possible advantages 
·· and disadvantages of taking protease lnhlbltor medications as dlrected. 
-+- For each numbered statement. please. mark one box with an ·r to rate HOW .IMPORTANT that 
statement is to you when you are thinking about whether to take your protease Inhibitor 
medication as directed. 
EXTREMELY IMPORTANT 5 · 
VERY IMPORTANT 4 
2. Taking my protease inhibitor medication as directed may delay 
some symptoms of HIV infection. 
4. Taking too many medications may not be good for my health.. 
6. Taking all of my protease inhibitor medication as directed ls 
too expensive. 
8. Taking my protease Inhibitor medication as directed may ma ke up 
for my unhealthy habits. 
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1 
0 0 
0 D 
OD 
DD 
OD 
DO 
0 0 
0 0 
D 0 
D 0 
D D 
D D 
D D 
0 D 
D 0 
0 0 
.D 
D 
D 
D 
D 
0 
D 
0 
(13/41) 
(13/421 
(13/43) 
(13/44) 
(13/45. 
(13/46 
(13/47 
(13/4€ 
( 
EXTREMELY IMPORTANT II 
VERY IMPORTANT 4 
MODERATELY IMPORTANT 3 
10. When I'm away from home or" on vacation. taking my protease 
Inhibitor medication as directed Is difficult. 
12. Taking my protease tnhlbitor medication as directed causes too 
many annoying side effects. 
14. I wony that taking all the doses that are prescribed might not 
be good for tne. · 
16. I wony that the protease .Inhibitor medication ls doing more 
harm than good. · · 
18. It may be hard on my system. If I take my protease tnhlbitor 
medication as directed. 
D 
D 
D 
D 
D 
0 
0 
D 
D 
0 
0 
D 
D 
D 
D 
D 
D 
D 
D 
0 
0 
0 
D D 
D D 
D D 
D 0 
D D 
D D 
D D 
0 D 
D D 
D D 
OD 
D 
D 
D 
0 
D 
0 
D 
D 
D 
D 
0 
(13/49) 
(13/50) 
(13/Sl) 
(13/52) 
(13/53) 
(13/54) 
(13/55) 
(13/56) 
(13/57) 
(13/58) 
(13/59) 
20. Taking my protease tnhlbitor medication as directed will help 
me feel better. 
0 OD DD (13/60) 
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Sometimes people take their medications as directed for a while, and then stop taking them 
for a while. 
- Thefollowing 2 questions are about how you are ta1cing your protease inhibitor medication RIGHT 
NOW. 
2 L Do you consistently take your protease Inhibitor medication as directed? ("as directed· 
means taking your medication at the right Ume and taking the prescribed amount) 
(13/611 
__ a . No. I do not. and I am not considering taking my protease inhibitor medication as 
directed. ··. 
__ b . No, I do not. but I am considering taking my protease inhibitor medication as directed. 
_. _ c. No, I do not. but I am planning to start taking my protease Inhibitor medication as 
dJrected within the next mo~th.. 
__ d. Yes, I consistently take my protease lnhlbitor medication as directed. 
I(ues. 
22. How long have you been taking your protease inhibitor medication as directed? (13/621 
a . 0-3 months 
b. 4-6 months 
c. 6-12 months 
d. more than 12 months 
Now here are some sltuatlons that might affect whether you take your protease inhibitor 
medication for HIV infection as directed. 
- For each situation. please mark one box with an ·x:- tO rote HOW TEMPTED you would be t.o skip 
your protease inhibit.or medication or take a dose which is dUf erentfrom the one prescribed. 
1 MODERATELY TEMPTED 3 
lsuGHTLY nMPTED 2 
I NOT TEMPTED· l 
5 
~J!i[eftlll®IB-tiJt:!ldfMWt4~& D D D D D 113/631 
24. When you are anxious about side effects. 0 0 0 0 0 (13/641 
26. When you wonder whether you really need your medication. 
28. When you experience minor side effects. 
30. When your doctor doesn't s eem interested in whether you take 
your med ication. 
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D D 0 D D . l13t65) 
D D 0 0 0 (13/66) 
D D 0 0 0 (13/67) 
D 0 D 0 0 (13/681 
0 0 0 0 0 (13/69) 
0 0 D 0 0 (13/70) 
3 1 
= 
EXTIU!:MELT TEMPTED IS 
VERY TEMPTED 4 
MODERATELY TEMPTED 3 
32. When side effects are anno~ng. 
0 0 0 0 D. u3m1 
0 0 0 0 0 (13/72) 
t~t  0 0 0 0 0 (13/73) 
34. When your medical condition doesn't seem that bad. 
36. When it seems too complex to keep track of all your medications. 
38. When your doctor doesn't explain why you need to take your 
medication. 
40. When you aren't sure If the medicirie Is really heiptng you. 
42. When you don't understand why you need your medieatlon. 
44. When your family or friends don't seem concerned enough about 
your condition. 
46. When your family or friends don't seem Interested In whether 
you take your medication. 
48. When your Insurance doesn't cover the cost of your medication. 
50. When you worry that taking too many medications might be 
bad for your health. 
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0 0 0 0 0 (13/7'.4) 
0 0 0 0 0 (13/75) 
0 0 0 0 0 (13/76] 
0 0 0 0 0 (13/77) 
0 0 0 0 0 (13/78) 
. D 0 0 0 0 (13/79) 
·D 0 0 0 0 (13/80) 
D 0 0 0 0 (14/1) 
D 0 0 0 0 .U4/21 
0 0 0 0 0 (14/3) 
D 0 0 0 0 (14/4) 
0 0 0 0 0 (14/S) 
D 0 d 0 0 (14/6] 
0 0 0 0 0 (14/7) 
D D D D D (14/8) 
D 0 0 D D (14/9) 
D D 0 D 0 1141101 
D D 0 D D 1141111 
\ 
= 
l EXTREMELY TEMPTED 
4 l VERY TEMPTE D 
J MODERATELY TEMPTED 3 
l SLIGHTLY TEMPTED 2 
r NOT TEMPTED 1 
52. When you worry that the chemicals In the medication might 
harm or hurt your body. 
D D D 0 D 1141121 
SECTION VI 
WAYS OF COPING WITH IIlV 
Here are some ways that different people may cope with HIV and its treatments. There are 
no right or wrong answers . 
.... In the last month, HOW OFTEN did .you think.feel, or do each item? 
· (Please circle one rwm.ber for each item) l VERT OFTEN 
l OFTEN 
l OCCASIONAILY 3 
RARELY 
1 
In the last month, I 
~·~~---· ·1 2 . felt the only thing to do was wait ............. .................... ................. l 
S.~~J~t~fit9.'l$:~1n•il'.iiiiJhMttlMili£.#.l.,.g,~1 l 
4. talked to someone to find out more ...... : ............... :, ................ :...... l 
BJfttJt!i~-~*~l«&ifl41WM~4':~D~\c~r:~~*- i 
6. tried not to close off options .... ......................................... .... ......... 1 
! 0 ' 1 
8. went along with fate ..................... .......................................•........ 1 
mm~tmi'fld*fl4Rl~it•vftlefS$1*1Srtdtm& 1 
10. tried to keep my feelings to myself .•..........•..•............................. :. 1 
B~&!W®iltl~t~Me™V!~illt.d 1 
12. slept more than usual. ................................................... ............. . 
14. was inspired to be creative .... ........ .... ......... ........... .................. .... . 
r:~"'g@~ ~~H *"1m'~J~r,im.w.~:m"';;i~~1d•11t"'·R·mmr''"'i&W?'F•··z~ ~~~T:9gfqru_ ~o.te1~!!W.-}flw.-"~'itts_;.<;:~'4l :-<.·•~':,!ri .. :.;#rt:.,~,.i.fil ,%¥<.& 
16. tried to get professional help ... ............... ...... ......................... ..... . . 
&i71!~HKrfi®iQ.m~J$Itii~~4'illra\fil"~'QQ:.~Y.~~'11ff.~fi.1.fll1~~tf'.~11 
18. waited to see what would ha ppen before ac ting ...... ......... . ... .... .... . 
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2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 
3 4 -
3 4 
3 4 
3 4 
3 4 
5 (14/13) 
5 (14/-14) 
5 (14/15) 
5 (14/16) 
5 (14/17) 
5 (14/18) 
5 (14/19) 
5 (14/20) 
5 (14/21) 
5 (14/22) 
5 (14/23) 
5 (14/24) 
5 (14/25) 
5 (14/261 
5 (14/27) 
5 (14/28) 
5 (14/29) 
I 
5 (14/30) 
?:·. 
VERY OFTEN I> 
OFTEN 4 
OCCASIONALLY 3 
IVJU':LY 2 
~~ti:~-fi-----~-20. let my feelings out somehow,_ .................. ..................................... . 
m1.-11\•",ii.,""'""'". · """'o· ·L1m~~~"Ae'i"1rn"Wr'l'(.;~"'llfrf~;o;<wror"""'"~..,.l"""w~·-··,,,,,..%.,"''''''""g)~ ~~ ... r.t~fM'""f""\1~ . : · . ...;.:$~ ... ~ c~a: . :rtm; ·v.4'.e%~·'f.S7t~fp':~~'@~~~~~,-:?.'~·~ 
22. talked to someone who could do something ......................•....•... .. 
l 
l 
l 
1 
24. took a big chance and did something risky .... ..................... ......... l 
~~. tID.:.~dtifdflc.ROmmttz~~f~%~t.-lb4tl~ i 
26. found new faith •.....•...........••.•••••••.•••.•.••.••••...••••.•••..•.•.••..••.......... l 
. ik~Atim1st~t~iie~ft6Uimifi.WW¥@£.U.¥Q.foii.t4¥M¥¥-WW i 
28. changed something so things will turn out................................... l 
~9 ·· -"'~..,.·~~"'%-~·-=•'d"'''"~'S!'!!!!ml~"""""""'-hlJ.4Y•'"''"::{,li'\~ mz~amwe~ ~~~ge9p.t9t+.f~.._.\~Rr.:~~~::r~~~~~~W*t~~f{~'°!~~~~f;~~~~~'l·~~·x· 
30. didn't let it get to me: refused to think about it ·............................ l 
~~~B-•t'i\Pre~B~~~l 
32. kept others from knowing how bad things were .....•.......... ... ... ..... l 
DB@1'Atiw~bitlftf~msit#i«sriifiT~~ i 
34. ta],ked to someone about how I was feeling................................... l 
R3~§:-0JR~tlf~~iraHW.@WQi.@i@MqtM.ll{¢4--.!Bfllii l 
36. drew on past experiences from similar situations ....•.•....••............ 
~~It~~~®!'i~tf~~ ~ -.~ • • • • • ~. ~  ,~ - ••• ~~  • ·• • • (I: ~ • . :t."-""t.se.: .$.nl
38. refused to believe it was happening ... ..•••••.••..•.....•.••...•.••..... , .•...... . 
mm~w~Bt<~:p1 ®.MQ.;;;;a.w1mtMM.~-mJ.iti 
1 
1 
1 
l 
40. tried to keep my feelings from interfering..................................... l 
lt~l~filli'~&'mgt&Y§R~tA¥4Jl®IMJ.l .... tJ~W'fil i 
42. wished the s ituation would go away or be over......... .................... 1 
~~e'W'A&!B~n~iti@tdJM@w~¥1111! i 
44. prayed ......... ... .•..........•....•.....•.•.....•.•..•••..•••••.••.••.....•.•••..•.•..•..••.•. 1 
~~.,rrnmo~·m11r~,:.~-A-~4.'''&;m~'W.i&##J!!™'~!~~ ~~R.@ttar~ep.J1Q~~~~~£tm~~~DVI .::.~.~.;wz~~~~~;q.;"Wt!f':; .. ~~~r.~~.z.r.w~~x~ 
46. went over In my mind what I would say or do .. .... ... ... : .... , ........... . 
~~~~~-~S9~~mwr~-=r~ 
48. reminded myself how much worse things could be ... ..•....... ... .. ... .. 
W9g'"'~~a· rv.'o"'iff;:{"d"""'o·wu'''wt ma'·s"11f'm;~.mu•'W"''f%@s.•lr~m·o3'J't~~-;n&¥iWM!.1.~wif.WJSWiff-li1@.jM>Jf~. ®l E~»)~~~,.i.t.La:,,.,~ .~::::£:..':«-;.:~~-w..;~kc~.:.:-:~lb%! .... ~Jl!.:-. tti~4~ ... !' ... 4.,•~c."ff~~ ·~:t~·<::. .. ·"r:~··!·~~~~r.,..~:~
50 . treated the Illness as a challenge ...................... ..... .. ....... ........ .... . 
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1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
. 4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
(14/3 l) 
(14/32) 
(14/33) 
(14/34) 
(14/35) 
(14/36) 
(14/371 
(14/381 
(14/391 
(14/401 
(14/41) 
(14/421 
(14/431 
(14/44) 
(14/45) 
(14/46) 
(14/471 
(14/48) 
(14/491 
(14/501 
(14/51) 
(14/521 
(14/53) 
(14/541 
(14/55) 
(14/56) 
(14/571 
(14/58) 
(14/591 
(14/60) 
(14/611 
(14/62) 
Now here are some questions about Injection (skin popping or IV) drugs. 
Please circle or fill in the correct response for each question. 
51. Have you ever used lnjectlon drugs? 
0 No 
0Yes, 
(14/63) 
-+-Please fill out the remaining questions only if you have ever used injection drugs. 
52. Do you use Injection drugs now? . 
0 No. not In the past 6 months 
0 Not now. but once or twice 1n the past 6 months 
0 Yes, occasionally · 
0 Yes, regularly 
If inlected at all during tfte past 6 months. 
-+- 53. During the past 6 months. how often have you Injected the following: 
LESS 
THAN 2-4 2-7 
TWICE TIMES TIMES 
PER PER PER 
NEVER MOl'fIH MOl'fIH WEEK 
a. Heroin by itself 0 0 0 0 
b. Cocaine by itself? 0 0 0 0 
c. Cocaine and heroin, or speedball? 0 0 0 0 
d. Amphetamines, such as uppers, 0 0 0 D 
speed. meth. or crack? 
MORE 
THAN 
ONCE 
PER 
DAY 
0 (14/65) 
0 (14/66) 
0 (14/67) 
0 (14/68) 
-+- 54. During the oast 6 months, how ofteri did you use a brand new needle or one that you are 
sure no one else used EACH TIME you shot up? (14/691 
0 Never 0Rarely 0 So.metlmes 0 Almost always OAiwa}rs 
..._ 55. During the past 6 months, how many people did you share needles or works with? U4noJ 
0 None 
0 1 other person 
0 2-3 differerit people 
0 4-10 dlffererit People 
0 More than 10 different people 
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..... 56. During the past 6 months. how often have: 
LESS MORE 
TilAN 2-4 2-7 TIIAN 
'IWICE TIMES TIMES ONCE 
PER PER PER PER 
NEVER MONTH MONTil WEEK DAY 
a. You used needles or works after 0 0 0 0 0 (14/71) 
someone without cleaning? 
b. Others used needles or.works after 0 0 0 0 0 (14/72) 
you without cleaning? 
c. You used a needle after someone 0 0 0 D 0 (14/T.l) 
who is mv positive had used it? 
d. You shot up in a shooting gallery. 0 D 0 0 0 (14/74) 
hit house or another place where 
groups of users shoot up? 
e. You shared rtnse water? 0 0 0 0 0 (14/7S) 
f. You shared a cooker? 0 0 0 0 0 (14/76) 
g. You shared cotton? 0 0 0 0 0 (14/77) 
..... 57. During the past 6 months. where did you get needles? 
~QME of your needl~ MQST of yQur n~dles 
(Answer yes or rw to all) (Check only one) 
YES NO 
ra~ut:e'&tte{'~~~~?4m D 0 D (14/78) 
b. On the street? 0 0 0 (14/79) 
tct~!§_~~ffgWJAAW?~ 0 . 0 0 (14/80) 
d. At a drugstore? 0 0 0 (15/1) 
0 0 0 (15/2) 
f. From a diabetic? 0 0 0 (15/3) 
0 0 0 (15/4) 
h. From another place not D 0 0 (IS/SJ 
mentioned? 
..... 58. During the past 6 months. if you haven't used a needle exchange. or lfyou had difficul-
ties getting needles from a needle exchartge. how come? (IS/6-11) 
Please check all that apply . 
0 Don't know about It 
0 Too far 
0 Open too few hours 
0 Scared of getting arrested 
0 Scared someone will see me there 
0 Other reason (please specify! ,115/12-321 
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59. Are you planning to use only your own works (needles. syringes. cotton. cooker, rinse 
water} or a brand new needle EVERY TIME you Inject within the next 6 months? If so. 
how soon? ll5/3Jl 
60. 
61. 
D 
D 
8 
D 
NO. l am not planning to start using new needles every time 
YES. within the next year 
YES. within the next 6 months 
YES, within the next month 
YES, I already use new needles every time 
: -
Have you been uslng new needles every tlme you use lV needles? 
If so, for how long? 
D NO, I have not been using using new needles every time 
D YES. for 30 days or less 
D YES. for MORE than 30 days but LESS than 6 months 
0 YES, for MORE than 6 months but LESS than a year 
D YES. for MORE than a year 
Now, how ready are you to STOP uslng injection drugs completely? 
O Notready 
0 Somewhat ready 
0 Ready 
O VeryReady 
For iriformation about needle exchange in Rhode Island. call (4{)1} 277-2320. 
(15/34) 
(15/35) 
For information on the "Medicationfor The Needy-Assistance Program· at The University of Rhode 
Island. call l-800-215-9001. 
This completes this survey. Thank youfor your assistance with this project &for sharing 
your thoughts on HIV related medications. · 
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SUPPLEMENT TO SECTION II 
MEDICATION #4 
MEDICINE NAME ________________ _ 
l. Th.ls medicine ls for. 
D HIV infection 
D To treat or prevent PCP (Pneumocystis carinii pneumonia) 
D To treat or prevent MAI (Mycobacterium avium complex) infection 
D To treat or prevent fungal infections (Candida or "tluush") D Other. ___________ _ 
D Don•tlmow 
2. How often do you take this medicine? 
D Two times a week 
D Tiu-ee times a week 
D Evexy other day 
D Onceaday 
D Two times a day 
D Tiu-ee times a day 
D Four times a day 
D Five times a day 
D Other:----------
3. How long have you been taking this. medication? 
Less than l month __ 6 months to l year 
l to 3 months __ 1 to 2 years 
4 ·to 6 months __ mqre than 2 years 
(15/36-55) 
(15/56) 
(15/57-76) 
(15/77) 
it6/1·2.0) 
4. During the last 3 months. have you ever stopped taking this medication because you felt 
better? · · (16/2 ll 
DYES .D NO 
5. During the last 3 months. have you ever stopped taking this medication because you felt 
worse? (16/221 
DYES D NO 
6. During the last 3 months. have you ever forgotten to take this medication? (16/23) 
DYES D NO 
7. During the last 3 months, have you at times been careless about taking this medication?(l6/24l 
DYES D NO 
8. During the last 3 months. have you ever taken less of this medicine than your doctor pre-
scribed because you felt better? (16/25) 
DYES D NO 
9. During the last 3 months. have you ever taken less of th.is medicine than yguf doctor pre· 
scribed because you felt worse? :. (16/261 
0 YES 0 NO 
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10. Since t/OU began taking this medication. have you ever purposely: 
a) taken more of the medicine than your 
physician prescribed? 
bl taken less of the medicine than your physician 
prescribed? 
c) discontinued or stopped taking your medication? 
YES NO 
D D 
D D 
0 D 
.... 11.a) How many times have you discontinued your medication for more 
than3 days? 
b) What were your reasons for discontinuing your medication? 
Please check all that apply 
. D My doctor recommended lt 
D Too many slde effects 
D I didn't want to be reminded of my Illness 
D Problems with insurance coverage 
D I didn't think it was working 
D Other.----------
(16/27) 
(16/28) 
(16/29] 
(16/30-31] 
(16/32-37] 
(38-57) 
12. Sometimes lt ls difficult to take prescnbed medicine all the time. During the past week, how 
many_tlmes did you miss a dose of MEDICATION 4? (16/58-59] 
13. During the past month, about how many times did you miss a dose of MEDICATION 4? 
(16/60-61] 
14. Durtng the past three months, about how many tiIµes did you miss a dose MEDICATION 4? 
(16/GZ-63] 
15. Please check any slde effect(s) you are having that you believe ai:e caused by this medicine: 
(16/64-79) 
D nausea 
D dizziness 
D vomiting . 
D abdominal pain 
D diarrhea 
D other. 
Unlucrslty of Rlvxk Island_ Ol 99G 
0 shortness of breath 
0 muscle aches 
0 fatigue 
0 tlngUng ln hands/feet 
0 numbness ln hands/feet 
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0 headaches 
D anxiety/worry 
0 "depression 
D rash 
0 sensltlvlty to sun 
--
(17/1 ·20) 
MEDICATION #5 
,MEDICINE NAME. _________ _ ______ _ 
l. Tills medicine Is for. 
0 HIV infection 
0 To treat or prevent PCP (Pneumocystls carinii pneumonia) 
0 To treat or prevent MAI" (Mycobacterlum avium complex) Infection 
0 To treat or prevent fungal Infections (Candida or ·Uuush·) 
0 Other. ·-
0 Don't lrnow 
2. . How often do you take this medicine? 
0 Two times a week 
0 Tilree times a week 
0 Every other day 
0 Once a day 
· 0 Two times a day 
0 Three times a day 
D Four times a day 
D Flve times a day 
D Other.---------
3. How long have you been taking this medication?-
Less than 1 month 
1to3 months 
4to6months 
__ 6 months to 1 year 
__ 1 to 2 years 
__ more than 2 years 
(1 7/ 2HO) 
(17/41) 
(17/42-QI) 
(17/62) 
(18/1-20) 
- (18/21) 
4 . Durtng the last 3 months, have you ever stopped tak.lng this medication because you fe~t 
better? (18/221 
DYES D NO 
5 . During the last 3 months. have you-ever stopped tak.lng this medication because you felt 
worse? (18/231 
DYES D NO 
6. During the last ·3 months, have you ever forgotten to take this ~edlcation? (18/24) 
DYES D NO 
7. Durtng the last 3 months, have you at times been careless ab~ut taking thls medlcatlon?(l8/2SJ 
DYES D NO 
8. During the last 3 months, have you ever taken less of this medicine tha n your doctor pre-
s cribed becau s e you felt better? (18/26) 
DYES 0 NO 
9. Durtng the last 3 months. have you ever taken less of this medicine than your doctor pre-
scribed becaus e you felt worse? (18/271 
0 YES 0 NO 
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10. Since you began taking this medication, have you ever purposely: 
a) taken more of the medicine than your 
physician prescribed? 
bl taken less of the medicine than your physician 
prescribed? 
c) discontinued or stopped taking your medication? 
YES NO 
0 0 
0 0 
0 0 
-- 11.a) How many times have you discontinued your medication for more 
than 3 days? 
b) What were your reasons for dlscontlnulng your medicatlon? 
Please check all that apply · 
.0 My doctor recommended lt 
0 Too many slde effects 
0 I didn•t want to be reminded of my illness 
0 Problems with Insurance coverage 
0 I didn't think lt was working 
0 Other: -----------
(18/28) 
(18/29) 
(18/30) 
(18/31-32) . 
(18/33-38] 
(18/39-58) 
12. Sometimes lt ls difficult to take prescnbed medicine all the time. During the past week, how 
many ~mes did you miss a dose of MEDICATION 5? (18/S9-60l 
13. During the past month, about how many tlmes did you mlss a dose of MEDICATION 5? 
(18/61-62) 
14. During the past three months, about how many times did you miss a dose MEDICATION 5? 
(18/63~) 
15. Please check any side efiect(s) you are having that you believe are caused by this medicine: 
0 nausea 
0 dizziness 
0 vomiting 
0 abdominal pain 
0 diarrhea 
0 other: 
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0 shortness of breath 
0 muscle aches 
0 fatigue 
0 tingling ID. hands/feet 
0 numbness ln hands/feet 
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. ll!l/65-80) 
0 headaclies 
0 anxiety/worry 
0 depression 
0 rash 
0 sensitivity to sun 
(19/1-20) 
.· . 
( 
MEDICATION #6 
MEDICINE NAME. __________ ______ _ 
L This medicine Is for: 
0 HIV Infection 
0 To treat or prevent PCP (PneumocystCs carinii pnewnonial 
0 To treat or prevent MAI (Mycobactertum avium complex) Infection 
0 To treat or prevent fungal Infections (Candida or "thrush") 
0 Other:------ ------0 Don't know 
2. How often do you take this medlcln~? 
0 Two times a week 
0 Tiiree times a week 
0 Every other day 
0 Once a day 
0 Two times a day 
0 Tiirec times a day 
0 Four tinies a day 
0 Five times a day 
0 Other:---------
3 . How long have you been taking this medication? 
Less than l month __ 6 months·to 1 year 
1 to 3 months __ l to 2 years 
4 to 6 months __ more than 2 years 
(1 9/21 -40) 
(19/41) 
(19/42-61) 
(19/62) 
(20/1·20) 
(20/21) 
4. Durlng the last 3 months, have you ever stopped taking this medication because you felt 
better? 1201221 
DYES 0 NO 
5 . During the last 3 months. have you ever stopped taking this medication because you felt 
worse? (20/231 
DYES D NO 
6. During the last 3 months. have you ever forgotten to take this medication? (20/24) 
DYES D NO 
7. During the last 3 months. have you at times been careless about taking this medicatlon?120/25J 
DYES . D NO 
8. During the last 3 months. have you ever taken less of this medicine than your doctor pre-
scribed becaus e you felt better? · (20/261 
DYES D NO 
9 . During the last 3 months. have you ever taken less of this medicine than your doctor pre-
s cribed because you felt worse? 1201211 
D YES D NO 
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10. Since you began taking lhis medlcallon. have you ever purposely: 
a) 
b) 
c) 
YES NO 
taken more of lhe medicine lhan you r 0 0 
phys ician prescribed? 
taken less of the medicine than your physician 0 0 
prescribed? 
discontinued or stopped taking your medication? 0 0 
~ 
-+- 11.a) How many times have you discontinued your medication for more 
than 3 days? 
. bl What were your reasons for discontinuing your medication? 
Please check aU that apply 
0 My doctor recommended It 
0 Too many side effects 
0 I didn't want to be reminded of my Illness 
0 Problems with Insurance coverage 
0 I didn't think it was working 
0 Other:----------
(20/28) 
(20/29) 
(20/30) 
(20/31-32) 
(20/33-38) 
(20/39-58) 
12. Sometimes it Is difficult to take prescribed medicine all the time_ During the past week, how 
many times did you miss a dose of MEDICATION 6? (20/59-60) 
13_ Duling the past month, about how many times did you mlss a dose of MEDICATION 6? 
(20/61-Q21 
14_ Duling the past three months, about hqw many times did you miss a dose MEDICATION 6? 
(20/63-64) 
15. Please check any side effect(s) y-0u are having that you believe are caused by this medicine: 
(20/65-00) 
0 nausea 
0 dizziness 
0 vomiting 
0 abdominal pain 
0 diarrhea 
0 other: 
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0 shortness of breath 
0 muscle aches 
0 fatigue 
0 tingling In hands/feet 
0 numbness In bands/feet 
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0 headaches 
0 anxiety /worry 
0 depression · 
0 rash 
0 sensltlvity to sun 
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1. Plot of Temptation to Skip Antiretroviral Medication on the 
Total Scale vs Age 
Plot of TTEMP*OI1. Legend: A = 1 obs, B = 2 obs, etc . 
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2. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Age 
Plot of TEMPSE*QI1 . Legend: A = 1 obs, B = 2 obs, etc. 
TEMPSE 
20 A 
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3. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Age 
Plot of TEMPLS*QI1. Legend: A = 1 obs, B = 2 obs, etc. 
TEMP LS 
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4. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Age 
Plot of TEMPFG*QI1 . Legend: A = 1 obs, B = 2 obs, etc. 
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5. Plot of Percent of Doses Missed in the past Week vs Age 
Plot of PDMWEEK*QI1. Legend: A = 1 obs, B = 2 obs, etc. 
PDMWEEK 
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NOTE: 4 obs had missing values. 
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6. Plot of Percent of Doses Missed in the past Month vs Age 
Plot of PDM1MTH*Ql1. Legend: A = 1 obs, B = 2 obs, etc. 
PDM1MTH 
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NOTE: 4 obs had missing values. 
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7. Plot of Percent of Doses Missed in past Three Months vs Age 
Plot of PDM3MTH*OI1. Legend: A= 1 obs, B = 2 obs, etc. 
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NOTE: 3 obs had missing values. 
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8. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Current Health Status 
Plot of TTEMP *QI3. Legend : A = 1 obs , B = 2 obs , etc . 
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9. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Current Health Status 
Plot of TEMPSE*OI3. Legend: A = 1 obs , B = 2 obs , etc. 
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NOTE: 3 obs hidden . 
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10. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Current Health Status 
Plot of TEMPLS*QI3. Legend: A = 1 obs, B = 2 obs , etc. 
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NOTE: 9 obs hidden. 
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11. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Current Health Status 
Plot of TEMPFG*QI3. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 9 obs hidden. 
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12. Plot of Percent of Doses Missed in the past Week vs Current 
Health Status 
Plot of PDMWEEK*QI3 . Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 4 obs had missing values. 25 obs hidden. 
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13. Plot of Percent of Doses Missed in the past Month vs Current 
Health Status 
Plot of PDM1MTH*OI3. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE : 4 obs had missing values. B obs hidden. 
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14. Plot of Percent of Doses Missed in the past Three Months vs 
Current Health Status 
Plot of PDM3MTH*QI3. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 3 obs had missing values. 5 obs hidden. 
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15. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Race 
Plot of TTEMP*OI4. Legend: A= 1 obs, B = 2 obs , etc . 
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NOTE: 6 obs hidden. 
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16. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Race 
Plot of TEMPSE*QI4. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE : 13 obs hidden. 
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17. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Race 
Plot of TEMPLS*OI4. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 29 obs hidden. 
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18. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Race 
Plot of TEMPFG*QI4 . Legend : A= 1 obs, B = 2 obs , etc. 
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NOTE: 27 obs hidden. 
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19. Plot of Percent of Doses Missed in the past Week vs Race 
Plot of POMWEEK*OI4 . Legend: A = 1 obs , B = 2 obs , etc. 
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16 
15 
14 A A 
13 A 
12 B 
11 A 
10 
9 
8 
7 E A A 
6 
5 0 A A A 
4 
3 
2 
0 A z c M s G 
0 2 3 4 5 6 
RACE 
NOTE: 4 obs had mi ssing values . 44 obs hi dden. 
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20. Plot of Percent of Doses Missed in the past Month vs Race 
Plot of PDM1MTH*OI4. Legend: A = 1 obs, B = 2 obs, etc. 
PDM1MTH 
25 A 
24 
23 
22 
21 
20 
19 A 
18 A A 
17 A 
16 B A 
15 A A A 
14 c A 
13 
12 B 
11 B A 
10 A A A 
9 A A 
8 A 
7 I A 
6 A A A 
5 B A 
4 A A 
3 H D B A 
2 B B B 
1 A A 
0 z A D M D 
0 2 3 4 5 6 
RACE 
NOTE: 4 obs had missing values. 24 obs hidden. 
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21. Plot of Percent of Doses Missed in the past Three Months vs Race 
Plot of PDM3MTH*QI4 . Legend: A = 1 obs, B = 2 obs, etc. 
PDM3MTH 
27 A 
26 
25 
24 
23 
22 
21 A 
20 
19 
18 A 
17 
16 A 
15 B 
14 A 
13 
12 A 
11 A A 
10 B B 
9 B 
8 G A 
7 A c 
6 D c 
5 D B 
4 E c A 
3 A A A A 
2 D c A 
F D B 
0 z B F L D 
0 2 3 4 5 6 
RACE 
NOTE: 3 obs had missing values . 16 obs hidden. 
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22. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Years of Education 
Plot of TTEMP *QI5 . Legend : A = 1 obs, B = 2 obs , etc . 
TTEMP 
50 A 
A 
A A A 
A 
40 A A 
A A A B A 
A 
A 
A B A 
30 A A 
A A 
A A A 
A A 
A A A A 
A B B 
B A c A B 
20 A B A 
A D B A 
A A 
B A D c B A c 
A A A A D A 
B A D B A B 
A B B B B l A H B B A B A A 
10 A 
A 
0 A A A 
3 4 5 6 7 B 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
YRS EDUCATION 
NOTE : 1 obs had mi ssing values. 
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23. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Years of Education 
Plot of TEMPSE*QI5. Legend: A = 1 obs, B = 2 obs, etc. 
TEMPSE 
20 A 
19 A 
18 A 
17 A 
16 A 
15 A A B A 
14 B A 
13 B B B 
12 A A A A 
11 B A A 
10 A A A A A A A 
9 A B A A B B B 
8 D A 
7 A B B A A B 
6 A A B A B A B A A 
5 B B A F B A c 
4 A D B B B R c H B c A B A A 
3 
2 A 
0 A A A 
3 4 5 6 7 8 9 1 0 11 12 13 1 4 15 1 6 17 18 19 20 21 22 
YRS EDUCATION 
NOTE: 1 obs had missing values. 
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24. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Years of Education 
Plot of TEMPLS*QI5. Legend: A = 1 obs, B = 2 obs, etc. 
TEMP LS 
20 A A 
19 
18 A 
17 
16 A A A 
15 A A 
14 A A 
13 A A 
12 B A 
11 A A A 
10 A A A A 
9 B A A 
8 A B A A c 
7 A B A A 
6 A E B 
5 A A B A A A A 
4 A A F F D c z H M B F A B A A 
3 A 
2 
0 A A A B 
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
YRS EDUCATION 
NOTE: 1 obs had missing values. 
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NOTE: 
25. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling good Scale vs Years of Education 
Plot of TEMPFG*OI5. Legend: A = 1 obs, B = 2 obs , etc. 
TEMPFG 
17 A 
16 A A A 
15 A 
14 A B 
13 A A A 
12 A A 
11 B A A 
10 c A B A B 
9 A A 
8 A A c B 
7 B A 
6 8 D B B 
5 c B B G 8 A A B 
4 A A D E c c v D K c G A B A A 
3 
2 
A A 
0 A A A 
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
YRS EDUCATION 
1 obs had missing values. 
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26. Plot of Percent of Doses Missed in the past Week vs Years of 
Education 
Plot of PDMWEEK*OI5 . Legend: A= 1 obs, B = 2 obs, etc. 
PDMWEEK 
21 A 
20 
19 A 
18 
17 A B 
16 
15 
14 A A 
13 A 
12 A A 
11 A 
10 
9 
8 
7 B B B A 
6 
5 A B A A A A 
4 
3 
2 
0 A A A G l H G Z G N C J B A A A 
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
YRS EDUCATION 
NOTE: 5 obs had missing values. 11 obs hidden. 
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27. Plot of Percent of Doses Missed in the past Month vs Years of 
Education 
Plot of PDM1MTH*QI5. Legend: A = 1 obs, B = 2 obs, etc . 
PDM1MTH 
25 A 
24 
23 
22 
21 
20 
19 A 
18 B 
17 A 
16 A A A 
15 A A A 
14 A A A A 
13 
12 A A 
11 B A 
10 A A A 
9 A A 
8 A 
7 D c B 
6 A A A 
5 A A A 
4 A A 
3 A B B F B A A 
2 D A A 
A A 
0 A E G E F x E c c B A A 
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
YRS EDUCATION 
NOTE: 5 obs had missing values. 
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28. Plot of Percent of Doses Missed in past Three Months vs Years of 
Education 
Plot of PDM3MTH*OI5. Legend: A = 1 obs, B = 2 obs, etc. 
PDM3MTH 
27 A 
26 
25 
24 
23 
22 
21 A 
20 
19 
18 A 
17 
16 A 
15 B 
14 A 
13 
12 A 
11 A A 
10 c A 
9 A A 
8 c A A A A A 
7 A A A A 
6 A B A A A A 
5 A A B B 
4 A c A c A 
3 A A A 
2 A A D A A 
1 A A G A A A 
0 A F F F G T E H B B A A A 
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
YRS EDUCATION 
NOTE: 4 obs had missing values. 
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29. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Annual Income 
Plot of TTEMP*OI19. Legend: A = 1 obs, B = 2 obs, etc . 
TTEMP 
50 A 
A 
c 
A 
40 A A 
F 
A 
A 
c A 
30 B 
A A 
A B 
A A 
B B 
A B A A 
D c A A 
20 c A 
E A A A 
B 
A H E A A 
E c A 
H c A A 
A v c D F c 
10 A 
A 
0 A B 
0 2 3 4 5 
ANNUAL INCOME 
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30. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Annual Income 
Plot of TEMPSE*QI19. Legend: A = 1 obs, B = 2 obs, etc. 
TEMPSE 
20 A 
19 A 
18 A 
17 A 
16 A 
15 A B B 
14 c 
13 c B A 
12 A B A 
11 D 
10 A E A 
9 A G A A A 
8 c A A 
7 A E B A 
6 F E A 
5 K B A c 
4 A z H E F c 
3 
2 A 
0 A B 
0 2 3 4 5 
ANNUAL INCOME 
NOTE: 2 obs hidden. 
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31. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Annual Income 
Plot of TEMPLS*Ql19. Legend: A = 1 obs, B = 2 obs, etc. 
TEMP LS 
20 A A 
19 
18 A 
17 
16 c 
15 B 
14 B 
13 B 
12 B A 
11 B A 
10 c A 
9 B A A 
8 A c B B 
7 B B A 
6 B D B 
5 A D B A 
4 c z L F H c 
3 A 
2 
0 c B 
0 2 3 4 5 
ANNUAL INCOME 
NOTE: 24 obs hidden . 
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32. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Annual Income 
Plot of TEMPFG*QI19. Legend: A = 1 obs, B = 2 obs, etc. 
TEMPFG 
17 A 
16 B A 
15 A 
14 c 
13 A B 
12 B 
11 D 
10 D c A A 
9 B 
8 A c B A 
7 B A 
6 A E c A 
5 M F A A 
4 c z J G H c 
3 
2 
B 
0 A B 
0 2 3 4 5 
ANNUAL INCOME 
NOTE: 12 obs hidden. 
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33. Plot of Percent of Doses Missed in the past Week vs Annual Income 
Plot of PDMWEEK*QI19. Legend: A = 1 obs, B = 2 obs, etc . 
PDMWEEK 
21 A 
20 
19 A A 
10 
17 A A A 
16 
15 
14 B 
13 A 
12 A A 
11 A 
10 
9 
8 
7 F A 
6 
5 c A B A 
4 
3 
2 
0 z T D D 
0 2 3 4 5 
ANNUAL INCOME 
NOTE : 4 obs had missing values. 41 obs hidden . 
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34. Plot of Percent of Doses Missed in the past Month vs Annual 
Income 
Plot of PDM1MTH*OI19. Legend: A = 1 obs, B 2 obs, etc. 
PDM1MTH 
25 A 
24 
23 
22 
21 
20 
19 A 
18 A A 
17 A 
16 A B 
15 c 
14 c A 
13 
12 B 
11 A B 
10 B A 
9 B 
8 A 
7 F A B A 
6 B A 
5 A B 
4 B 
3 B K A A 
2 B A B A 
1 A A 
0 E z N B E c 
0 2 3 4 5 
ANNUAL INCOME 
NOTE: 4 obs had missing values. 17 obs hidden. 
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35. Plot of Percent of Doses Missed in past Three Months vs Annual 
Income 
Plot of PDM3MTH*QI19. Legend: A = 1 obs, B 2 obs, etc. 
PDM3MTH 
27 A 
26 
25 
24 
23 
22 
21 A 
20 
19 
18 A 
17 
16 A 
15 B 
14 A 
13 
12 A 
11 A A 
10 c A 
9 A A 
8 F A A 
7 A c 
6 D B A 
5 D A A 
4 A D A c 
3 A c 
2 A E B 
1 F A B c 
0 D z N B E c 
0 2 3 4 5 
ANNUAL INCOME 
NOTE: 3 obs had missing values. 12 obs hidden. 
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36. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Persons in Household 
Plot of TTEMP*QI8. Legend: A = 1 obs, B = 2 obs, etc. 
TTEMP 
50 
A 
AA A 
A 
40 B 
AAA 
A 
AB 
30 A 
A 
B 
A 
A A 
A AA A 
DA 
20 A A 
CB 
A 
BDAAA 
BCA A 
CBA AA 
FKDA B AB A 
10 A 
A 
0 B 
0 10 20 30 40 50 60 70 80 90 
# IN HOUSEHOLD 
NOTE: 49 obs had missing values . 
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37. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Persons in Household 
Plot of TEMPSE*QI8. Legend: A = 1 obs, 8 = 2 obs, etc. 
TEMPSE 
20 A 
19 A 
18 A 
17 
16 
15 8 A A 
14 AA A 
13 AA A 
12 8 
11 A A 
10 A B A 
9 DAAA 
8 A AA 
7 BA A 
6 BC A A 
5 EEA A 
4 IMFAAC AB A 
3 
2 A 
0 B 
0 10 20 30 40 50 60 70 80 90 
# IN HOUSEHOLD 
NOTE: 49 obs had missing values. 
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38. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Persons in Household 
Plot of TEMPLS*QI8. Legend: A = 1 obs, 8 = 2 obs, etc. 
TEMP LS 
20 A 
19 
18 A 
17 
16 AA 
15 A 
14 A A 
13 A 
12 B 
11 A A 
10 AA A 
9 AA 
8 CA B A 
7 AA 
6 BCA A 
5 AA A 
4 PSGCACA AB A 
3 
2 
0 CA 
0 10 20 30 40 50 60 70 80 90 
# IN HOUSEHOLD 
NOTE : 49 obs had missing values . 
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39. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Persons in Household 
Plot of TEMPFG*QIS. Legend: A = 1 obs, B = 2 obs, etc. 
TEMPFG 
17 A 
16 c 
15 A 
14 A A 
13 A 
12 A 
11 AA A 
10 BBA 
9 A A 
8 BA A 
7 AA 
6 BB B 
5 GB AB 
4 JRIBABA AB A 
3 
2 
AA 
0 B 
0 10 20 30 40 50 60 70 80 
# IN HOUSEHOLD 
NOTE: 49 obs had missing values. 
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40. Plot of Percent of Doses Missed in the past Week vs Persons in 
Household 
Plot of PDMWEEK*OI8. Legend: A = 1 obs, B = 2 obs, etc . 
PDMWEEK 
21 A 
20 
19 AA 
18 
17 A 
16 
15 
14 A 
13 
12 A A 
11 A 
10 
9 
8 
7 AB B A 
6 
5 BAB 
4 
3 
2 
0 YUICCCA BA A A A 
0 11 22 33 44 55 66 77 88 
# IN HOUSEHOLD 
NOTE: 53 obs had missing values. 
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41. Plot of Percent of Doses Missed in the past Month vs Persons in 
Household 
Plot of PDM1MTH*QI8. Legend: A = 1 obs, B = 2 obs, etc. 
PDM1MTH 
25 
24 
23 
22 
21 
20 
19 A 
18 B 
17 A 
16 c 
15 B 
14 A 
13 
12 AA 
11 A A A 
10 A 
9 A 
8 
7 BB 
6 AA A 
5 B 
4 A A 
3 E A A A 
2 BB A 
1 A 
0 QJGCBCA BA A A 
0 11 22 33 44 55 66 77 88 
# IN HOUSEHOLD 
NOTE: 53 obs had missing values. 
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42. Plot of Percent of Doses Missed in past Three Months vs Persons 
in Household 
Plot of PDM3MTH•ar8 . Legend: A = 1 obs, B = 2 obs, etc. 
PDM3MTH 
27 A 
26 
25 
24 
23 
22 
21 
20 
19 
18 
17 
16 A 
15 A 
14 
13 
12 A 
11 
10 A 
9 AA 
8 BCA 
7 AA 
6 BC 
5 CAA 
4 AAA 
3 A A 
2 FA A 
1 ABA AA 
0 PLFCBBA BA A A 
0 11 22 33 44 55 66 77 B8 
# IN HOUSEHOLD 
NOTE: 52 obs had missing values. 
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43. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Duration since HIV Positive 
Plot of TTEMP*QI29. Legend: A = 1 obs, B = 2 obs, etc. 
TTEMP 
50 A 
A 
c 
A 
40 A A 
A E 
A 
A 
A c 
30 B 
A A 
A B 
A A 
c A 
A A c 
A B A E 
20 D 
A B E 
A A 
A B D 
A B F 
A B J 
A A c G z 
10 A 
A 
0 A B 
0 2 3 4 5 6 
HOW LONG AGO DIAGNOSED? 
NOTE: 1 obs hidden. 
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44. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Duration since HIV Positive 
Plot of TEMPSE*OI29. Legend: A = 1 obs, B = 2 obs, etc. 
TEMPSE 
20 A 
19 A 
18 A 
17 A 
16 A 
15 A A c 
14 A B 
13 A A D 
12 A c 
11 A c 
10 B E 
9 A c G 
8 A A c 
7 A A A F 
6 A B D E 
5 A B D J 
4 A A E z 
3 
2 A 
0 A B 
0 2 3 4 5 6 
HOW LONG AGO DIAGNOSED? 
NOTE: 9 obs hidden. 
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45. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Duration since HIV Positive 
Plot of TEMPLS*QI29. Legend: A = 1 obs , B = 2 obs , etc. 
TEMP LS 
20 A A 
19 
18 A 
17 
16 A B 
15 A A 
14 A A 
13 B 
12 B A 
11 c 
10 A B A 
9 B B 
8 A A A E 
7 B c 
6 A A F 
5 A B E 
4 A c A H M z 
3 A 
2 
0 A A c 
0 2 3 4 5 6 
HOW LONG AGO DIAGNOSED? 
NOTE : 30 obs hidden . 
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46. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Duration since HIV Positive 
Plot of TEMPFG*QI29. Legend: A = 1 obs, B = 2 obs, etc. 
TEMPFG 
17 A 
16 A A A 
15 A 
14 c 
13 A B 
12 B 
11 A B A 
10 A A G 
9 A A 
8 A F 
7 A A A 
6 A B A F 
5 A c D M 
4 A B c F L z 
3 
2 
A A 
0 A B 
0 2 3 4 5 6 
HOW LONG AGO DIAGNOSED? 
NOTE: 19 obs hidden. 
141 
( 
47. Plot of Percent of Doses Missed in the past Week vs Duration 
since HIV Positive 
Plot of PDMWEEK*OI29. Legend: A = 1 obs, B = 2 obs, etc. 
PDMWEEK 
21 A 
20 
19 A A 
18 
17 A B 
16 
15 
14 A A 
13 A 
12 A A 
11 A 
10 
9 
8 
7 A B D 
6 
5 B E 
4 
3 
2 
0 c A D B L s z 
0 2 3 4 5 6 
HOW LONG AGO DIAGNOSED? 
NOTE: 4 obs had missing values. 46 obs hidden. 
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48. Plot of Percent of Doses Missed in the past Month vs Duration 
since HIV Positive 
Plot of PDM1MTH*OI29. Legend : A = 1 obs, B = 2 obs, etc. 
PDM1MTH 
25 A 
24 
23 
22 
21 
20 
19 A 
18 A A 
17 A 
16 A B 
15 A B 
14 A A B 
13 
12 A A 
11 c 
10 A B 
9 B 
8 A 
7 A A A G 
6 A B 
5 A B 
4 A A 
3 A E I 
2 F 
A A 
0 c A D B E M z 
0 2 3 4 5 6 
HOW LONG AGO DIAGNOSED? 
NOTE: 4 obs had missing values. 18 obs hidden. 
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49. Plot of Percent of Doses Missed in the past Three Months vs 
Duration since HIV Positive 
Plot of PDM3MTH*QI29. Legend: A = 1 obs, B 2 obs, etc. 
PDM3MTH 
27 
26 
25 
24 
23 
22 
21 A 
20 
19 
18 
17 
16 A 
15 
14 
13 
12 
11 A 
10 B A 
9 A 
8 A A 
7 A A 
6 A 
5 A A 
4 A A 
3 A A 
2 B B 
1 A D 
0 c A D B E I 
0 2 3 4 5 
HOW LONG AGO DIAGNOSED? 
NOTE: 3 obs had missing values. 16 obs hidden. 
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50. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs T-Cell Count 
Plot of TTEMP*QI31 . Legend: A = 1 obs, B = 2 obs, etc. 
TTEMP 
50 A 
A 
A A A 
A 
40 A A 
A B c 
A 
A 
B A A 
30 B 
B 
A B 
B 
A B A 
c B 
D B c 
20 A B A 
A D c 
A A 
B I D A 
A D B B 
c c F A 
c E p H G 
10 A 
A 
0 A A A 
0 2 3 4 
T-CELL COUNT LAST TESTED 
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51. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs T-Cell Count 
Plot of TEMPSE *OI31 . Legend: A = 1 obs, B = 2 obs, etc. 
TEMP SE 
20 A 
19 A 
10 A 
17 A 
16 A 
15 B A A A 
14 B A 
13 A c B 
12 B B 
11 B A A 
10 c c A 
9 D G 
B B A B 
7 B F A 
6 B G c 
5 A B G F A 
4 c G s M 
3 
2 A 
0 A A A 
0 2 3 4 
T-CELL COUNT LAST TESTED 
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53. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs T-Cell Count 
Plot of TEMPFG*QI31. Legend: A = 1 obs, B = 2 obs, etc. 
TEMPFG 
17 A 
16 A A A 
15 A 
14 A B 
13 A B 
12 B 
11 A B A 
10 B c D 
9 A A 
8 B B B A 
7 A A A 
6 E B c 
5 c F H D 
4 c H z s J 
3 
2 
A A 
0 A A A 
0 2 3 4 
T-CELL COUNT LAST TESTED 
NOTE: 3 obs hidden. 
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54. Plot of Percent of Doses Missed in the past Week vs T-Cell Count 
Plot of PDMWEEK*QI31. Legend: A = 1 obs, B = 2 obs, etc. 
PDMWEEK 
21 A 
20 
19 A A 
18 
17 A A A 
16 
15 
14 A A 
13 A 
12 A A 
11 A 
10 
9 
8 
7 B B B A 
6 
5 B c B 
4 
3 
2 
0 G M z z p 
0 2 3 4 
T-CELL COUNT LAST TESTED 
NOTE: 4 obs had missing values . 25 obs hidden. 
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55. Plot of Percent of Doses Missed in the past Month vs T-Cell Count 
Plot of PDM1MTH*OI31. Legend: A = 1 obs, B = 2 obs, etc. 
PDM1MTH 
25 A 
24 
23 
22 
21 
20 
19 A 
18 A A 
17 
16 A B 
15 B 
14 B A 
13 
12 B 
11 A A 
10 c 
9 A 
e A 
7 c D c 
6 A B 
5 B 
4 A A 
3 B c J 
2 B c 
A A 
0 G I x T 
0 2 3 
T-CELL COUNT LAST TESTED 
NOTE : 4 obs had missing values. 
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56. Plot of Percent of Doses Missed in the past Three Months vs T-
Cell Count 
Plot of PDM3MTH•QI31. Legend: A = 1 obs, B = 2 obs , etc. 
PDM3MTH 
27 A 
26 
25 
24 
23 
22 
21 A 
20 
19 
10 A 
17 
16 A 
15 A A 
14 A 
13 
12 
11 B 
10 A A 
9 B 
B A E 
7 D 
6 A B c 
5 c B 
4 B c D 
3 B B 
2 A G 
1 c E D 
0 G I v p 
0 2 3 
T-CELL COUNT LAST TESTED 
NOTE: 3 obs had missing values. 
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57. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs General Mental Health 
Plot of TTEMP*TGMH. Legend: A = 1 obs, 8 = 2 obs, etc. 
TTEMP 
50 
A 
A A 
A 
40 A A 
A A A A A A 
A 
A A A 
30 A A 
A A 
A 8 
A A 
A A A 
A A 8 A 
A A 8 A 8 A A 
20 A 8 
A A A c A A 
A A 
8 8 A c c c 8 
A A A A D 
A 8 A A 8 A A A 8 A 
A E A c D D D c D 8 A c A A 
10 A 
0 A A A 
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 
TGMH 
NOTE: 10 obs had missing values. 
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58. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs General Mental Health 
Plot of TEMPSE*TGMH. Legend: A = 1 obs, B = 2 obs, etc. 
TEMPSE 
20 A 
19 A 
18 A 
17 
16 A 
15 A A A A 
14 A A A 
13 A A A A A A 
12 B A A 
11 A A 
10 A A B A A 
9 A A B c B B 
8 A A A A A 
7 A A B A B A 
6 A B A A D B 
5 A A A B B A A D B A A 
4 A E E D D E D F E B B c A A A 
3 
2 
0 A A A 
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 
TGMH 
NOTE: 10 obs had missing values. 
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60. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs General Mental Health 
Plot of TEMPFG*TGMH. Legend: A = 1 obs, B = 2 obs , etc . 
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NOTE: 10 obs had missing values. 
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62. Plot of Percent of Doses Missed in the past Month vs General 
Mental Health 
Plot of PDM1MTH*TGMH. Legend: A = 1 obs, B = 2 obs, etc. 
PDM1MTH 
25 A 
24 
23 
22 
21 
20 
19 A 
18 A A 
17 A 
16 A A A 
15 A A 
14 A A A A 
13 
12 A A 
11 A A 
10 A A A 
9 A A 
8 A 
7 B A B B A B 
6 A A A 
5 A A A 
4 A A 
3 A A B A B c A A A A 
2 A A A A A 
1 A A 
0 A B B D c c H G G G F F B E B A 
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 
TGMH 
NOTE: 14 obs had missing values. 
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63. Plot of Percent of Doses Missed in the past Three Months vs 
General Mental Health 
Plot of PDM3MTH*TGMH. Legend: A = 1 obs, B 2 obs, etc. 
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NOTE: 13 obs had missing values. 
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64. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Vitality, Energy or Fatigue 
Plot of TTEMP*TVEF. Legend: A = 1 obs, B = 2 obs, etc. 
TTEMP 
50 
A 
A A 
A 
40 A A 
A A A c 
A 
B B 
30 A A 
A 
B A 
A A 
A A A 
A c A 
A A A A A c A 
20 A A A 
A A B B A A 
A A 
A A E B B c 
A A B B A A 
D F A A A 
A c B D D E G D c D B 
10 A 
0 A A 
0 5 10 15 20 25 30 35 40 45 50 55 60 65 
TVEF 
NOTE: 11 obs had missing values. 
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65. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Vitality, Energy or Fatigue 
Plot of TEMPSE*TVEF . Legend : A = 1 obs , B = 2 obs, etc . 
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NOTE: 11 obs had missing values. 
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66. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Vitality, Energy or Fatigue 
Plot of TEMPLS·TVEF . Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 11 obs had missing values. 
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67. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Vitality, Energy or Fatigue 
Plot of TEMPFG*TVEF. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 11 obs had missing values. 
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68. Plot of Percent of Doses Missed in the past Week vs Vitality, 
Energy or Fatigue 
Plot of PDMWEEK*TVEF. Legend : A = 1 obs, B = 2 obs, etc. 
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NOTE: 15 obs had missing values. 
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69. Plot of Percent of Doses Missed in the past Month vs Vitality, 
Energy or Fatigue 
Plot of PDM1MTH*TVEF. Legend: A = 1 obs , B = 2 obs, etc. 
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NOTE : 15 obs had missing values. 
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70. Plot of Percent of Doses Missed in the past Three Months vs 
Vitality, Energy or Fatigue 
Plot of PDM3MTH*TVEF. Legend: A = 1 obs, B = 2 obs , etc. 
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NOTE: 14 obs had missing values. 
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71. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Severity of Bodily Pain 
Plot of TTEMP*QI24 . Legend: A = 1 obs, B = 2 obs, etc . 
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72. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Severity of Bodily Pain 
Plot of TEMPSE *QI24. Legend : A = 1 obs , B = 2 obs, etc. 
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73. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Severity of Bodily Pain 
Plot of TEMPLS*OI24. Legend: A = 1 obs, B = 2 obs, etc. 
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74. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Severity of Bodily Pain 
Plot of TEMPFG*QI24. Legend: A = 1 obs, B = 2 obs, etc. 
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75. Plot of Percent of Doses Missed in the past Week vs Severity of 
Bodily Pain 
Plot of PDMWEEK*QI24 . Legend : A = 1 obs, B = 2 obs , etc . 
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NOTE: 4 obs had missing values. 14 obs hidden. 
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76. Plot of Percent of Doses Missed in the past Month vs 
Severity of Bodily Pain 
Plot of PDM1MTH*OI24. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 4 obs had missing values. 
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77. Plot of Percent of Doses Missed in the past Three Months vs 
Severity of Bodily Pain 
Plot of PDM3MTH •OI24. Legend: A = 1 obs, B = 2 obs, etc . 
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78. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Interference of Pain with Normal Work 
Plot of TTEMP*QI25. Legend: A = 1 obs, B = 2 obs, etc. 
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79. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Interference of Pain with Normal Work 
Plot of TEMPSE*OI25 . Legend: A = 1 obs, B = 2 obs, etc. 
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80. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Interference of Pain with Normal Work 
Plot of TEMPLS*QJ25. Legend: A = 1 obs , B = 2 obs , etc . 
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NOTE: 7 obs hidden. 
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81. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Interference of Pain with Normal Work 
Plot of TEMPFG*0125. Legend: A = 1 obs, B = 2 obs, etc . 
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NOTE: 6 obs hidden. 
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82. Plot of Percent of Doses Missed in the past Week vs Interference 
of Pain with Normal Work 
Plot of PDMWEEK*QI25. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 4 obs had missing values . 18 obs hidden. 
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83. Plot of Percent of Doses Missed in the past Month vs Interference 
of Pain with Normal Work 
Plot of PDM1MTH*QI25. Legend: A = 1 obs, B = 2 obs, etc . 
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NOTE: 4 obs had missing values. 1 obs hidden. 
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84. Plot of Percent of Doses Missed in the past Three Months vs 
Interference of Pain with Normal Work 
Plot of PDM3MTH*QI25. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 3 obs had missing values. 
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85. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Days in Bed 
Plot of TTEMP*QI26. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE : 4 obs had missing values. 
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86. Plot of Temptation to Skip Antiretroviral Medication on the Side Effects 
Scale vs Days in Bed 
Plot of TEMPSE*QI26. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 4 obs had missing values. 
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87. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Days in Bed 
Plot of TEMPLS*OI26. Legend: A= 1 obs, B = 2 obs, etc. 
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NOTE : 4 obs had missing values . 12 obs hidden. 
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88. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Days in Bed 
Plot of TEMPFG*QI26. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 4 obs had missing values. 11 obs hidden. 
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89. Plot of Percent of Doses Missed in the past Week vs Days in Bed 
Plot of PDMWEEK*OI26. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 8 obs had missing values. 30 obs hidden. 
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90. Plot of Percent of Doses Missed in the past Month vs Days in Bed 
Plot of PDM1MTH*QI26. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 8 obs had missing values. 10 obs hidden. 
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91. Plot of Percent of Doses Missed in the past Three Months vs Days 
in Bed 
Plot of PDM3MTH*QI26. Legend: A = 1 obs , B 2 obs, etc. 
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NOTE : 7 obs had missing values . 6 obs hidden . 
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92. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Hospitalizations 
Plot of TTEMP*0127. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 2 obs had missing values. 1 obs hidden. 
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93. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Hospitalizations 
Plot of TEMPSE *OI27. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 2 obs had missing values. 8 obs hidden . 
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94. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Hospitalizations 
Plot of TEMPLS*QI27. Legend : A = 1 obs, B = 2 obs, etc. 
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NOTE: 2 obs had missing values. 27 obs hidden. 
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95. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Hospitalizations 
Plot of TEMPFG*QI27. Legend: A = 1 obs, B = 2 obs, etc . 
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NOTE: 2 obs had missing values. 20 obs hidden. 
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96. Plot of Percent of Doses Missed in the past Week vs 
Hospitalizations 
Plot of PDMWEEK*OI27. Legend: A= 1 obs, B = 2 obs, etc. 
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97. Plot of Percent of Doses Missed in the past Month vs 
Hospitalizations 
Plot of PDM1MTH•QI27. Legend: A= 1 obs, B = 2 obs, etc. 
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NOTE: 6 obs had missing values. 23 obs hidden. 
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98. Plot of Percent of Doses Missed in the past Three Months vs 
Hospitalizations 
Plot of PDM3MTH*QI27. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 5 obs had missing values. 18 obs hidden . 
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99. Plot of Temptation to Skip Antiretroviral Medication on the Total 
Scale vs Persons giving Emotional Support 
Plot of TTEMP *QI 12 . Legend : A = 1 obs , B = 2 obs , etc . 
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NOTE: 24 obs had missing values. 
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101. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Persons giving Emotional Support 
Plot of TEMPLS*QI12. Legend: A= 1 obs, B = 2 obs, etc . 
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NOTE: 24 obs had missing values. 
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102. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Persons giving Emotional Support 
Plot of TEMPFG*QI12. Legend: A= 1 obs, B = 2 obs, etc . 
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NOTE: 24 obs had missing values. 
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103. Plot of Percent of Doses Missed in the past Week vs Persons 
giving Emotional Support 
Plot of PDMWEEK*QI12. Legend : A = 1 obs, B = 2 obs, etc. 
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NOTE: 28 obs had missing values . 
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104. Plot of Percent of Doses Missed in the past Month vs Persons 
giving Emotional Support 
Plot of PDM1MTH*OI12. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 28 obs had missing values. 
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105. Plot of Percent of Doses Missed in the past Three Months vs 
Persons giving Emotional Support 
Plot of PDM3MTH*Ol12 . Legend: A= 1 obs, B = 2 obs, etc. 
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NOTE: 27 obs had missing values. 
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106. Plot of Temptation to Skip Antiretroviral Medication on the 
Total Scale vs Persons giving Financial Support 
Plot of TTEMP *QI13 . Legend: A = 1 obs, B = 2 obs , etc . 
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NOTE: 51 obs had missing values . 
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107. Plot of Temptation to Skip Antiretroviral Medication on the Side 
Effects Scale vs Persons giving Emotional Support 
Plot of TEMPSE*OI13. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 51 obs had missing values. 
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108. Plot of Temptation to Skip Antiretroviral Medication on the Lack 
of Support Scale vs Persons giving Emotional Support 
Plot of TEMPLS*QI13. Legend: A = 1 obs, B = 2 obs, etc. 
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NOTE: 51 obs had missing values. 
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109. Plot of Temptation to Skip Antiretroviral Medication on the 
Feeling Good Scale vs Persons giving Financial Support 
Plot of TEMPFG*OI13. Legend: A = 1 obs, B = 2 obs, etc. 
TEMPFG 
17 
16 A A A 
15 
14 A A 
13 A 
12 
11 A A A 
10 A A A A A 
9 A A 
8 c 
7 A A 
6 A A B A 
5 D E B A c 
4 L K J B E B A c A A A 
3 
2 
A 
0 A 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
# FINANCIAL HELP 
NOTE: 51 obs had missing values. 
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110. Plot of Percent of Doses Missed in the past Week vs Persons 
giving Financial Support 
Plot of PDMWEEK•QI13. Legend: A= 1 obs, B = 2 obs, etc. 
PDMWEEK 
21 A 
20 
19 A A 
18 
17 A 
16 
15 
14 B 
13 
12 A A 
11 
10 
9 
8 
7 B B A A 
6 
5 A A A A 
4 
3 
2 
0 U Q K F D C A A D A A A 
A 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
# FINANCIAL HELP 
NOTE: 53 obs had missing values. 
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111. Plot of Percent of Doses Missed in the past Month vs Persons 
giving Financial Support 
Plot of PDM1MTH*OI13. Legend: A = 1 obs, B = 2 obs, etc. 
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112. Plot of Percent of Doses Missed in the past Three Months vs 
Persons giving Financial Support 
Plot of PDM3MTH*QI13. Legend: A= 1 obs, B = 2 obs, etc. 
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